Truven Health Analytics 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document (USD $)	12 Months Ended
	Dec. 31, 2013
Document Information [Line Items]	'
Entity Registrant Name	'Truven Holding Corp.
Entity Central Index Key	'0001571116
Current Fiscal Year End Date	'--12-31
Entity Well-known Seasoned Issuer	'No
Entity Voluntary Filers	'No
Entity Current Reporting Status	'Yes
Entity Filer Category	'Non-accelerated Filer
Entity Public Float	$0
Document Type	'10-K
Document Period End Date	31-Dec-13
Document Fiscal Year Focus	'2013
Document Fiscal Period Focus	'FY
Amendment Flag	'false
Entity Common Stock, Shares Outstanding	1
Truven Health Analytics, Inc.	'
Document Information [Line Items]	'
Entity Registrant Name	'Truven Health Analytics Inc.
Entity Central Index Key	'0001571117
Entity Public Float	$0
Entity Common Stock, Shares Outstanding	1

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$10,255	$23,805
Trade and other receivables (less allowances of $1,530 and $1,865, respectively)	97,798	105,141
Prepaid expenses and other current assets	24,208	18,409
Deferred tax assets	0	10,648
Total current assets	132,261	158,003
Computer hardware and other property, net	48,037	40,191
Developed technology and content, net	148,637	160,335
Goodwill	457,677	824,339
Other identifiable intangible assets, net	362,014	396,473
Other noncurrent assets	15,977	17,786
Total assets	1,164,603	1,597,127
Current liabilities	'	'
Accounts payable and accrued expenses	53,376	92,507
Deferred revenue	128,392	122,319
Current portion of long-term debt	5,350	5,276
Capital lease obligation	1,596	0
Deferred tax liabilities	711	0
Income taxes payable	189	82
Total current liabilities	189,614	220,184
Deferred revenue	2,096	5,354
Capital lease obligation	2,102	0
Long-term debt	866,908	832,696
Deferred tax liabilities	22,027	118,675
Other noncurrent liabilities	2,573	966
Total liabilities	1,085,320	1,177,875
Equity	'	'
Common stock—$ 0.01 par value; 1,000 shares authorized, 1 share issued and outstanding at December 31, 2013 and December 31, 2012	0	0
Additional paid-in capital	478,549	473,364
Accumulated deficit	-399,101	-54,112
Foreign currency translation adjustment	-165	0
Total equity	79,283	419,252
Total liabilities and equity	$1,164,603	$1,597,127

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Allowance for Doubtful Accounts Receivables	$1,530	$1,865
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	1,000	1,000
Common stock, share issued (in shares)	1	1
Common stock, shares outstanding (in shares)	1	1

Consolidated_and_Combined_Stat

Consolidated and Combined Statements of Comprehensive Income (Loss) (USD $)	9 Months Ended	12 Months Ended	5 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2013	Jun. 06, 2012	Dec. 31, 2011
			Predecessor	Predecessor
Revenues, net	$241,786	$492,702	$208,998	$483,207
Operating costs and expenses Cost of revenues, excluding depreciation and amortization	-141,558	-265,541	-112,050	-245,609
Selling and marketing, excluding depreciation and amortization	-30,958	-56,157	-25,917	-54,814
General and administrative, excluding depreciation and amortization	-13,042	-41,042	-27,173	-44,867
Allocation of costs from Predecessor Parent and affiliates	0	0	-10,003	-34,496
Depreciation	-6,700	-21,219	-6,805	-14,851
Amortization of developed technology and content	-15,470	-31,894	-12,460	-24,208
Amortization of other identifiable intangible assets	-19,527	-34,460	-8,226	-19,691
Goodwill impairment	0	-366,662	0	0
Other operating expenses	-49,622	-35,038	-18,803	-20,002
Total operating costs and expenses	-276,877	-852,013	-221,437	-458,538
Operating income (loss)	-35,091	-359,311	-12,439	24,669
Net interest income from Predecessor Parent	0	0	0	134
Interest expense	-49,014	-70,581	0	-63
Interest income	0	0	3	0
Other finance costs	0	-24	0	0
Income (loss) before income taxes	-84,105	-429,916	-12,436	24,740
Benefit from (Provision for) income taxes	29,993	84,927	4,803	-9,859
Net income (loss)	-54,112	-344,989	-7,633	14,881
Other comprehensive income (loss):	'	'	'	'
Foreign currency translation adjustments	0	-165	0	0
Total comprehensive income (loss)	($54,112)	($345,154)	($7,633)	$14,881

Consolidated_and_Combined_Stat1

Consolidated and Combined Statements of Cash Flows (USD $)	9 Months Ended	12 Months Ended	5 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2013	Jun. 06, 2012	Dec. 31, 2011
			Predecessor	Predecessor
Operating activities	'	'	'	'
Net income (loss)	($54,112)	($344,989)	($7,633)	$14,881
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'	'	'
Depreciation	6,700	21,219	6,805	14,851
Amortization of developed technology and content	15,470	31,894	12,460	24,208
Amortization of other identifiable intangible assets	19,527	34,460	8,226	19,691
Amortization of debt issuance costs	1,626	2,557	0	0
Amortization of debt discount	1,101	2,643	0	0
Amortization of unfavorable leasehold interest	-60	-94	0	0
Loss on extinguishment of debt	5,110	2,353	0	0
Goodwill impairment	0	366,662	0	0
Deferred income tax (benefit) provision	-30,075	-85,398	543	5,884
Share-based compensation expense	329	1,457	2,519	1,349
Retention bonus in conjunction with the Acquisition	8,635	1,378	5,800	0
Changes in operating assets and liabilities:	'	'	'	'
Trade and other receivables	-27,544	7,644	32,869	3,914
Prepaid expenses and other current assets	-6,436	-5,690	388	-5,289
Accounts payable and accrued expenses	39,593	-40,385	-21,582	10,499
Bank overdrafts	0	0	-2,630	-55
Deferred revenue	47,433	2,815	-19,739	-6,315
Income taxes	0	107	-514	1,450
Other, net	55	2	294	-51
Net cash provided by (used in) operating activities	27,352	-1,365	17,806	85,017
Investing activities	'	'	'	'
Acquisitions, net of cash acquired	-1,249,402	0	0	0
Increase in notes receivable from VCPH Holding LLC	0	-300	0	0
Capital expenditures	-31,270	-43,485	-10,285	-40,521
Net cash used in investing activities	-1,280,672	-43,785	-10,285	-40,521
Financing activities	'	'	'	'
Issuance of common stock	464,400	0	0	0
Additional capital contribution	0	2,350	0	0
Proceeds from senior term loan, net of original issue discount	517,125	0	0	0
Proceeds from senior notes, net of original issue discount	325,007	0	0	0
Proceeds from revolving credit facility	0	30,000	0	0
Principal repayment of senior term loan	-2,638	-5,332	0	0
Proceeds from senior term loan related to refinancing	166,995	86,105	0	0
Principal repayment of senior term loan related to refinancing	-166,995	-74,773	0	0
Premium payment for refinancing the credit facility	-5,153	-5,760	0	0
Payment of debt issuance costs	-21,616	0	0	0
Payment of capital lease obligation	0	-825	0	0
Decrease in net investment of Predecessor Parent	0	0	-16,760	-53,020
Decrease in notes receivable from Predecessor Parent	0	0	9,247	8,361
Net cash provided by (used in) financing activities	1,277,125	31,765	-7,513	-44,659
Effect of exchange rate changes in cash	0	-165	0	0
Increase (decrease) in cash and cash equivalents	23,805	-13,550	8	-163
Cash and cash equivalents	'	'	'	'
Beginning of period	'	23,805	70	233
End of period	23,805	10,255	78	70
Supplemental cash flow disclosures	'	'	'	'
Interest paid	36,299	62,095	0	111
Income taxes paid	0	420	129	53
Income tax refunds	0	0	0	702
Noncash dividend received	$0	$0	$0	$177

Consolidated_and_Combined_Stat2

Consolidated and Combined Statements of Equity (USD $)	Total	Common stock	Additional paid-in capital	Accumulated deficit	Accumulated other comprehensive loss	Net investment of Predecessor Parent
In Thousands, unless otherwise specified
Balance at beginning period at Dec. 31, 2010	'	'	'	'	'	$568,089
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Decrease in net investment of Predecessor Parent	'	'	'	'	'	-228,671
Net income (loss)	'	'	'	'	'	14,881
Foreign currency translation adjustments	'	'	'	'	'	0
Balance at ending period at Dec. 31, 2011	'	'	'	'	'	354,299
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Decrease in net investment of Predecessor Parent	'	'	'	'	'	-8,440
Net income (loss)	'	'	'	'	'	-7,633
Foreign currency translation adjustments	'	'	'	'	'	0
Balance at ending period at Jun. 06, 2012	'	'	'	'	'	338,226
Balance at beginning period at Mar. 31, 2012	'	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Retention bonus in conjunction with the Acquisition	'	'	'	'	'	5,800
Balance at ending period at Jun. 06, 2012	'	'	'	'	'	338,226
Balance at beginning period at Apr. 20, 2012	'	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Net income (loss)	-54,112	'	'	-54,112	'	'
Additional capital contribution	464,400	'	464,400	'	'	'
Retention bonus in conjunction with the Acquisition	8,635	'	8,635	'	'	'
Share-based compensation expense	329	'	329	'	'	'
Foreign currency translation adjustments	0	'	'	'	'	'
Balance at ending period at Dec. 31, 2012	419,252	0	473,364	-54,112	0	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Net income (loss)	-344,989	'	'	-344,989	'	'
Additional capital contribution	2,350	'	2,350	'	'	'
Retention bonus in conjunction with the Acquisition	1,378	'	1,378	'	'	'
Share-based compensation expense	1,457	'	1,457	'	'	'
Foreign currency translation adjustments	-165	'	'	'	-165	'
Balance at ending period at Dec. 31, 2013	$79,283	$0	$478,549	($399,101)	($165)	'

Description_of_Business_and_Ba

Description of Business and Basis of Presentation (Notes)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Description of Business and Basis of Presentation	'
	Description of Business and Basis of Presentation
	Description of the Business
	On April 23, 2012, VCPH Holding Corp. (now known as Truven Holding Corp., (the “Company”)), an affiliate of Veritas Capital Fund Management, L.L.C. (“Veritas Capital” or the “Sponsor”), entered into the Stock and Asset Purchase Agreement with Thomson Reuters U.S. Inc. (“TRUSI”) and Thomson Reuters Global Resources (“TRGR”), both affiliates of the Thomson Reuters Corporation (“the Stock and Asset Purchase Agreement”), which the Company assigned to Wolverine Healthcare Analytics, Inc. (“Wolverine”) on May 24, 2012. Wolverine is an affiliate of The Veritas Fund IV, L.P., a fund managed by Veritas Capital. Pursuant to the Stock and Asset Purchase Agreement, on June 6, 2012, Wolverine acquired 100% of the equity interests of Thomson Reuters (Healthcare) Inc. (“TRHI”) from TRUSI and certain other assets and liabilities of the Thomson Reuters Healthcare business from TRGR and its affiliates (the “Acquisition”). Upon the closing of the Acquisition, Wolverine merged with and into TRHI, with TRHI surviving the merger (the “Merger”) as a direct wholly-owned subsidiary of the Company, and subsequently changed its name to Truven Health Analytics Inc. (“Truven”). Following the Merger, the assets acquired and liabilities assumed are owned by Truven, which remains a direct wholly-owned owned subsidiary of the Company.
	Truven provides healthcare data and analytics solutions and services to key constituents in the healthcare system, including employers and health plans, federal government agencies, state government agencies, hospitals, clinicians and pharmaceutical companies. Truven operates and manages its business under three reportable segments: Payer, Hospitals and Clinicians.
	The Company was formed on April 20, 2012 by Veritas Capital for the purpose of consummating the Acquisition and has had no operations from inception other than its investment in Truven.
	Basis of Presentation
	The consolidated and combined financial statements of Successor and combined financial statements of our Predecessor have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). All significant intercompany balances and transactions have been eliminated in the consolidated and combined financial statements.
	Successor-The consolidated financial statements as of December 31, 2013, and for the periods from April 20, 2012 through December 31, 2012 and from January 1, 2013 through December 31, 2013 include the accounts of the Company from inception and its subsidiaries subsequent to the closing of the Acquisition on June 6, 2012. The consolidated financial statements of the Successor reflect the Acquisition under the acquisition method of accounting, in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combinations.
	Predecessor-The accompanying combined financial statements of the Thomson Reuters Healthcare business (our “Predecessor”) prior to the Acquisition, include the combined financial statements of TRHI and certain assets owned by subsidiaries of Thomson Reuters Corporation (“Thomson Reuters” or the “Predecessor Parent”).
	Before the Acquisition, our Predecessor operated as a business unit of Thomson Reuters and not as a standalone company. TRHI was a wholly-owned indirect subsidiary of Thomson Reuters, and certain of the company's assets were owned by subsidiaries of Thomson Reuters. During the Predecessor Period, TRHI engaged in extensive intercompany transactions with Thomson Reuters and its subsidiaries related to certain support services, and Thomson Reuters allocated the cost of these services as “Allocation of costs from Predecessor Parent and affiliates” in the combined statement of comprehensive income (loss) (see Note 18). For the Predecessor Period, the accompanying combined financial statements reflect the assets, liabilities, revenues and expenses directly attributed to the Thomson Reuters Healthcare business as well as certain allocations by the Predecessor Parent. All significant transactions in the Predecessor Period between TRHI and other Thomson Reuters entities were included in our Predecessor's combined financial statements. The expense and cost allocations were determined on bases that were deemed reasonable by management in order to reflect the utilization of services provided or the benefit received by TRHI during the periods presented. The combined financial information included herein does not necessarily reflect the results of operations, financial position, changes in equity and cash flows of the Company in the future or what would have been reflected had we operated as a separate, standalone entity during the periods presented. The income tax benefits and provisions, related tax payments and deferred tax balances were prepared as if the Predecessor had operated as a standalone taxpayer for the Predecessor Periods presented.
	From January 1, 2009 to June 30, 2011, our Predecessor was reported on a combined basis with Thomson Reuters’ former Scientific segment to form the Healthcare and Science segment of the Predecessor Parent. Effective June 30, 2011, our Predecessor was reported separately following the Predecessor Parent’s announcement of its intention to dispose of the Thomson Reuters Healthcare business. Reflecting the manner in which the business was managed in each period, certain shared costs of the combined Healthcare and Science segment incurred prior to June 30, 2011, were allocated to our Predecessor and are reported within “Allocation of costs from Predecessor Parent and affiliates.” Subsequent to June 30, 2011, these costs are included within “General and administrative, excluding depreciation and amortization” in the combined statement of comprehensive income (loss).
	“Notes receivable from Predecessor Parent” is separately identified on the combined balance sheet, as it relates to a specific agreement between TRHI and the Predecessor Parent. All other intercompany activity with the Predecessor Parent or affiliates, which was not subject to written loan agreements, was included in “Net investment of Predecessor Parent” in the combined balance sheet. All transactions recorded through the “Net investment of Predecessor Parent,” with the exception of the noncash dividend discussed in Note 18, are reflected as financing activities in the accompanying combined statements of cash flows.
	The Company is a wholly-owned subsidiary of VCPH Holdings LLC (“Holdings LLC”) and has no operations other than its investment in Truven. Therefore, the condensed consolidated and combined financial statements of the Company reflect the financial position and results of operations of Truven.
	Reclassification
	In order to conform the Predecessor Period with the Successor Period presentation, the Company has reclassified facilities costs previously recorded in the “General and administrative, excluding depreciation and amortization” to “Costs of revenues, excluding depreciation and amortization” and “Selling and marketing, excluding depreciation and amortization” accounts amounting to $3.3 million and $0.4 million, respectively, in the Predecessor Period from January 1, 2012 to June 6, 2012, $4.5 million and $0.5 million, respectively, in the Successor Period from inception (April 20, 2012) to December 31, 2012, and $7.3 million and $0.8 million respectively, in the Predecessor Period ended December 31, 2011. These reclassifications did not have an impact on the Company’s balance sheet and statement of cash flows for the periods presented.
	Revision on Segment reporting
	During 2013, the Company identified errors in the allocation of depreciation and amortization within the reportable segments which impacted the period from inception (April 20, 2012) to December 31, 2012 (Successor), the period from January 1, 2012 to June 6, 2012 (Predecessor), and the year ended December 31, 2011 (Predecessor). In evaluating whether the Company’s previously issued consolidated and combined financial statements were materially misstated, the Company considered the guidance in ASC Topic 250, Accounting Changes and Error Corrections, ASC Topic 250-10-S99-1, Assessing Materiality, and ASC Topic 250-10-S99-2, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements. Management determined these errors were not material, individually or in the aggregate, to any of the previously issued financial statements. Revisions to the applicable prior periods are reflected in the financial information herein and will be reflected in future filings containing such financial information. The revision had no net impact on the Company’s consolidated balance sheet, consolidated statements of comprehensive income (loss) and of cash flows for any prior period.
	The following table summarizes the effects of the revision on the Company's segment reporting:
	Segment information from inception (April 20, 2012) to December 31, 2012 (Successor):
		As Reported			Adjustments				As Revised
		Depreciation and amortization	Segment operating income		Depreciation and amortization		Segment operating income		Depreciation and amortization	Segment operating income
	Payer	10,276	27,762		702		(702	)	10,978	27,060
	Hospitals	6,983	3,722		(631	)	631		6,352	4,353
	Clinicians	3,578	4,493		1,262		(1,262	)	4,840	3,231
	Segment total	20,837	35,977		1,333		(1,333	)	22,170	34,644
	Center	1,333	(1,919	)	(1,333	)	1,333		—	(586	)
	Total	22,170	34,058		—		—		22,170	34,058
	Segment information from period January 1, 2012 to June 6, 2012 (Predecessor):
		As Reported			Adjustments				As Revised
		Depreciation and amortization	Segment operating income		Depreciation and amortization		Segment operating income		Depreciation and amortization	Segment operating income
	Payer	8,249	16,701		1,290		(1,290	)	9,539	15,411
	Hospitals	6,516	7,226		(996	)	996		5,520	8,222
	Clinicians	3,480	15,073		726		(726	)	4,206	14,347
	Segment total	18,245	39,000		1,020		(1,020	)	19,265	37,980
	Center	1,020	(24,410	)	(1,020	)	1,020		—	(23,390	)
	Total	19,265	14,590		—		—		19,265	14,590
	Segment information for the period December 31, 2011 (Predecessor):
		As Reported			Adjustments				As Revised
		Depreciation and amortization	Segment operating income		Depreciation and amortization		Segment operating income		Depreciation and amortization	Segment operating income
	Payer	22,430	38,743		1,365		(1,365	)	23,795	37,378
	Hospitals	8,535	30,019		788		(788	)	9,323	29,231
	Clinicians	5,354	34,333		587		(587	)	5,941	33,746
	Segment total	36,319	103,095		2,740		(2,740	)	39,059	100,355
	Center	2,740	(38,733	)	(2,740	)	2,740		—	(35,993	)
	Total	39,059	64,362		—		—		39,059	64,362

Significant_Accounting_Policie

Significant Accounting Policies (Notes)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	Significant Accounting Policies
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates are based on management’s knowledge of current events and actions that the Company may undertake in the future, actual results could differ from those estimates. These estimates include, but are not limited to, allowance for doubtful accounts, realization of deferred tax assets, the determination of fair values used in the assessment of the realizability of long lived assets, goodwill and identifiable intangible assets, purchase accounting and the allocation of certain expenses to TRHI by TRUSI with respect to the Predecessor combined financial statements.
	Acquisitions
	Acquisitions are accounted for using the acquisition method in accordance with the Financial Accounting Standards Board (“FASB”) ASC Topic 805, Business Combinations, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition. The excess of the cost of an acquired entity over the amounts assigned to assets acquired and liabilities assumed in a business combination is recognized as goodwill. The results of acquired businesses are included in the consolidated and combined financial statements from the dates of acquisition.
	Transaction costs that the Company incurs in connection with an acquisition are expensed as incurred. During the measurement period the Company reports provisional information for a business combination if by the end of the reporting period in which the combination occurs the accounting is incomplete. The measurement period, however, ends at the earlier of when the acquirer has received all of the necessary information to determine the fair values or one year from the date of the acquisition. The finalization of the valuations may result in the refinement of assumptions that impact not only the recognized value of such assets, but also amortization and depreciation expense. In accordance with ASC 805 and the Company’s policy, any adjustments on finalization of the preliminary purchase accounting are recognized retrospectively from the date of acquisition.
	Revenue recognition
	The Company recognizes revenue when all of the following four criteria are met:
	•persuasive evidence of an arrangement exists;
	•delivery has occurred or services have been rendered;
	•the fee is fixed or determinable; and
	•collectability is reasonably assured.
	Subscription based products
	Subscription revenues from sales of products and services that are delivered under a contract over a period of time are recognized on a straight line basis over the term of the subscription. Where applicable, usage fees above a base period fee are recognized as services are delivered. Subscription revenue received or receivable in advance of the delivery of services or publications is included in deferred revenue.
	Multiple element arrangements
	The Company’s hosting arrangements are typically comprised of two deliverables: (1) the design, production, testing and installation of the customer’s database; and (2) the provision of ongoing data management and support services in conjunction with licensed data and software. Such deliverables are accounted for as separate units of accounting if the following criteria are met:
		For contracts entered into prior to January 1, 2011, revenue is allocated to a deliverable if vendor specific objective evidence (“VSOE”) or third party evidence (“TPE”) for that deliverable is available. The amount allocated to each deliverable is then recognized as revenue when delivery has occurred or services have been rendered with respect to that deliverable, provided that all other relevant revenue recognition criteria are met. VSOE generally exists only when the Company sells the deliverables separately and is the price actually charged by the Company for that deliverable. For contracts entered into prior to January 1, 2011, the Company is not able to establish VSOE or TPE for the deliverables in its hosting arrangements. As a result, such deliverables are treated as one unit of accounting, and the revenue is recognized over the ongoing service period.
		For contracts entered into or materially modified on or after January 1, 2011, revenue is allocated to deliverables based upon the following hierarchy: (i) VSOE; (ii) TPE; and (iii) best estimate of selling price (“ESP”). The objective of ESP is to determine the price at which the Company would offer each unit of accounting to customers if each unit were sold regularly on a standalone basis. The Company uses a cost plus a reasonable margin approach to determine ESP for each deliverable. Revenue related to database production is recognized using a proportional performance model, with reference to labor hours. Revenue related to ongoing services is recognized on a straight line basis over the applicable service period, provided that all other relevant criteria are met. For contracts entered into on or after January 1, 2011, the Company was able to separate the production of the database installation deliverable and the ongoing services deliverable into two separate units of accounting given that the deliverables have value to the customer on a standalone basis. The revenue is allocated to these units of accounting based upon relative ESP.
	Software-related products and services
	Certain arrangements include implementation services as well as term licenses to software and other software related elements, such as post contract customer support. Revenues from implementation services associated with installed software arrangements are accounted for separately from software and subscription revenues using the proportional performance model, with reference to labor hours, if VSOE is available for the elements of the arrangement. If the implementation services do not qualify for separate accounting, they are recognized together with the related software and subscription revenues on a straight line basis over the term of service.
	Advertising costs
	Costs incurred for producing and communicating advertising are expensed when incurred. Advertising expenses were $2,753 for the Successor Period ended December 31, 2013, $2,153 for the Successor Period from April 20, 2012 to December 31, 2012, $1,018 for the Predecessor Period from January 1, 2012 to June 6, 2012, and $3,313 for the year ended December 31, 2011.
	Research and development costs
	Research and development (“R&D”) costs are expensed as incurred. The R&D costs expensed were $1,704 for the Successor Period ended December 31, 2013, $534 for the Successor Period from April 20, 2012 to December 31, 2012, $1,586 for the Predecessor Period from January 1, 2012 to June 6, 2012, and $6,605 for the year ended December 31, 2011.
	Cash and cash equivalents
	Cash and cash equivalents are comprised of cash on deposit in banks. Cash equivalents have original maturities of less than 90 days. During the Predecessor Period, TRHI and the Predecessor Parent had an agreement whereby the Predecessor Parent periodically swept TRHI’s cash receipts and funded TRHI’s cash disbursements. With the exception of activity associated with “Notes receivable from Predecessor Parent,” described below, such activity is included in “Net investment of Predecessor Parent” on the combined balance sheet.
	Trade receivables and concentration of credit risk
	Trade receivables are classified as current assets and are reported net of an allowance for doubtful accounts. The Company assesses the allowance for doubtful accounts periodically, evaluating general factors such as the length of time individual receivables are past due, historical collection experience, and the economic and competitive environment. Management believes that the allowances at December 31, 2013 and 2012 are adequate to cover potential credit loss.
	No single customer or group of related customers accounted for more than 10% of the Company’s trade receivables as of December 31, 2013 and 2012. There was no revenue from a single customer or group of related customers that accounted for 10% or more of the Company’s revenues in the year ended December 31, 2013, the Successor Period from April 20, 2012 to December 31, 2012 and the Predecessor Period from January 1, 2012 to June 6, 2012. Revenue from one customer from the Payer segment amounted to $52,985 or 11% of the Company’s revenues in 2011.
	Notes receivable from predecessor parent
	During the Predecessor Period, certain of TRHI’s cash transactions with the Predecessor Parent were subjected to written loan agreements specifying repayment terms and interest payments. The term of the agreements was one year, which was automatically renewed from year to year unless one of the parties notified the other in writing of termination. These notes are reflected separately in noncurrent assets in the combined balance sheet. As the notes were part of the Predecessor Parent’s overall capitalization of TRHI, changes in the receivables, with the exception of the noncash dividend discussed in Note 18, are reflected as financing activities in the statements of cash flows. An agreement existed between TRHI and the Predecessor Parent whereby the Predecessor Parent was required to pay interest to TRHI equal to the average monthly rate earned by the Predecessor Parent on its cash investments held with its primary US banker. TRHI paid interest to the Predecessor Parent at the rate earned by the Predecessor Parent on its cash investments plus 75 basis points. Interest on these notes is reflected in “Interest income from Predecessor Parent” in the statement of comprehensive income (loss).
	Computer hardware and other property
	Computer Hardware and Other Property are stated at cost less accumulated depreciation. Depreciation is computed on a straight line basis over the following estimated useful lives:
	Computer hardware	3-5 years
	Furniture, fixtures and equipment	5-7 years
	Leasehold improvements	Lesser of lease term  or
		estimated useful life
	Developed technology and content
	Certain costs incurred in connection with software to be used internally are capitalized once a project has progressed beyond a conceptual, preliminary stage to that of application development stage. Costs that qualify for capitalization include both internal and external costs, but are limited to those that are directly related to a specific project. The capitalized amounts, net of accumulated amortization, are included in “Developed technology and content, net” on the balance sheets.
	Developed technology and content is stated at cost less accumulated amortization. Amortization is computed based on the expected useful life of three to ten years.
	Goodwill and other identifiable intangible assets
	Goodwill is tested for impairment annually on November 1 of each year, or more frequently if indications of potential impairment exist. The Company performs a qualitative assessment (Step zero analysis) by identifying relevant events and circumstances such as industry specific trends, performance against forecasts and other indicators on a reporting unit level to determine whether it is necessary to perform the two step goodwill impairment test. For purposes of the goodwill impairment test, the reporting units of the Company, after considering the requirements of ASC 350, and the relevant provisions of the Segment Reporting Topic of the Codification, ASC 280, and related interpretive literature, represents the three reportable segments: Payer; Hospitals; and Clinicians. Under the two step approach, the first step is to determine the fair value of the reporting unit. Fair value is determined considering the income approach (discounted cash flow) and market approach. If the fair value of a reporting unit is less than its carrying value, this is an indicator that the goodwill assigned to that reporting unit may be impaired. In this case, the second step is to allocate the fair value of the reporting unit to the assets and liabilities of the reporting unit, as if they had just been acquired in a business combination for the fair value of the reporting unit. The excess of the fair value of the reporting unit over the amounts allocated to its assets and liabilities is referred to as the implied fair value of goodwill. The implied fair value of the reporting unit’s goodwill is then compared to the actual carrying value of goodwill. If the implied fair value is less than the carrying value, an impairment loss is recognized for that excess.
	Identifiable intangible assets with finite lives are amortized over their estimated useful lives. The carrying values of identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. The estimated useful lives for these identifiable intangible assets are as follows:
	Trade names	15 years
	Customer relationships	11-12 years
	Impairment of long lived assets
	Management evaluates the impairment of long-lived assets whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. The initial test for impairment compares the carrying amounts with the sum of undiscounted cash flows related to the asset. If the carrying value is greater than the undiscounted cash flows of the asset, the asset is written down to its estimated fair value.
	Deferred Financing Costs
	Deferred financing costs are incurred to obtain long-term financing and are amortized over the terms of the related debt. The amortization of deferred financing costs is classified as interest expense in the statement of comprehensive loss and totaled $2,557 and $1,626 for the year ended December 31, 2013 and for the Successor Period from April 20, 2012 to December 31, 2012, respectively. The unamortized portion of deferred financing costs amounted to $13,902 and $17,409, as of December 31, 2013 and December 31, 2012, respectively.
	Debt and Original Issue Discounts
	On initial recognition, debts are measured at face value less original issue discount. Subsequent to initial recognition, interest bearing debts are measured at amortized cost. Original issue discount is amortized based on an effective interest rate method over the term of the debt. Original issue discount is presented net of debt in the Company’s consolidated balance sheet.
	Fair Value Measurement
	Fair value is defined under the Fair Value Measurements and Disclosures Topic of the Codification, ASC 820, as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard established a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:
	Level 1-Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.
	Level 2-Inputs, other than quoted prices included within Level 1, which are observable for the asset or liability, either directly or indirectly. These are typically obtained from readily-available pricing sources for comparable instruments.
	Level 3-Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own assumptions of the data that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.
	Under the Financial Instruments Topic of the Codification, ASC 825, entities are permitted to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value measurement option under ASC 825 for any of its financial assets or liabilities.
	Share-based compensation plans
	The Predecessor Parent administered all share-based compensation plans on behalf of TRHI and applied the fair value recognition provisions of ASC 718, Compensation-Stock Compensation (“ASC 718”), to calculate the effect of such compensation on our Predecessor’s comprehensive loss in the Predecessor Period.
	Following the Acquisition, the Company’s immediate parent, Holdings LLC, established a compensation award in accordance with the Amended and Restated Limited Liability Company Operating Agreement of Holdings LLC (the “Operating Agreement”) to provide Class B Membership Interests in Holdings LLC to certain executive officers of the Company. The equity awards are accounted for by applying the fair value recognition provisions of ASC 718, to calculate the effect of such compensation on the Company’s net income in the Successor Periods.
	Income taxes
	The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”).
	For the Predecessor Period, income taxes are presented as if the Company operated as a separate standalone taxpaying entity (separate return basis). Income taxes payable by subsidiaries that file separate returns are included in “Income taxes payable” on the combined balance sheet. The Predecessor Parent files individual and combined tax returns that include TRHI as required within each jurisdiction.
In the consolidated Successor financial statements, the Company utilizes the asset and liability method of accounting for income taxes, which requires that deferred tax assets and liabilities be recorded to reflect the future tax consequences of temporary differences between the book and tax basis of various assets and liabilities. A valuation allowance is established to offset any deferred tax assets if, based upon the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
ASC 740 also provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements. ASC 740 requires evaluation of tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax position is “more likely than not” to be sustained by the applicable tax authority. Interest and penalties arising from an uncertain income tax position is included in our provision for income taxes. The Company did not have any material uncertain tax positions.
Recent accounting pronouncements
In February 2013, the FASB issued Accounting Standards Update No. 2013-02, Comprehensive Income (Topic 220) ("ASU 2013-02"). The amendments in ASU 2013-02 supersede and replace the presentation requirements for reclassifications out of accumulated other comprehensive income in ASU 2011-05 and ASU 2011-12 for all public and private organizations. The amendments would require an entity to provide additional information about reclassifications out of accumulated other comprehensive income. The amendments in ASU 2013-02 are effective prospectively for fiscal years, and periods within those years, beginning after December 15, 2012. The Company adopted ASU 2013-02 effective January 1, 2013. The adoption of this standard had no impact on the Company’s financial statements.
In July 2013, the FASB issued ASU 2013-11, Income taxes (Topic 740):Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The amendment requires an unrecognized tax benefit or portion of an unrecognized tax benefit to be presented as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward except when certain conditions exist. The amendment in ASU 2013-11 is effective for the Company for fiscal years beginning after December 15, 2013, including periods in 2014. The adoption of this standard will not impact the Company's financial position, comprehensive loss or cash flows.

Acquisition_Notes

Acquisition (Notes)	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Acquisition	'
	Acquisition
	On June 6, 2012, as fully described in Note 1, the Company completed the Acquisition of the Thomson Reuters Healthcare business (subsequently renamed Truven Health Analytics Inc. (“Truven”)) from subsidiaries of the Thomson Reuters Corporation for net cash consideration of $1,249,402. The direct costs associated with the Acquisition amounted to $26,734 and were recorded as period costs.
	There were no pre-closing or post-closing purchase price adjustments. The Company financed the Acquisition and paid related costs and expenses associated with the Acquisition and the financing as follows: (i) approximately $464,400 in common equity was contributed by entities affiliated with the Sponsor and certain co-investors; (ii) $527,625 principal amount was borrowed under the Term Loan Facility; and (iii) $327,150 aggregated principal amount of Notes (as defined below) were issued.
	On June 6, 2013, the Company finalized the acquisition date fair values of acquired assets and liabilities, including the valuations of identifiable intangible assets, computer hardware and other equipment, and developed technology and content. The determination of fair value of acquired assets involves a variety of assumptions, including estimates associated with useful lives. The finalization of these valuations and completion of management review of certain accounts resulted in the refinement of certain assets and liabilities and that resulted in a reduction of $533 to goodwill and a corresponding increase in current asset, noncurrent asset and noncurrent deferred tax liabilities of $458, $120 and $45, respectively, from the previously reported amounts as of December 31, 2012 and March 31, 2013. In accordance with the Company's accounting policy described in Note 2, the adjustments on finalization of the purchase accounting were recognized retrospectively to the date of acquisition.
	The following is a summary of the final allocation of the final purchase price of the Acquisition to the estimated fair values of assets acquired and liabilities assumed in the Acquisition. The final allocation of the purchase price is based on management's judgment after evaluating several factors, including a valuation assessment prepared by a third party valuation firm:
		Final values recognized at acquisition date
	Trade and other receivables	$	77,598
	Prepaid assets and other current assets	11,973
	Computer hardware and other property	24,693
	Developed technology and content	159,622
	Other identifiable intangible assets	416,000
	Other noncurrent assets	106
	Current deferred tax assets	11,262
	Current liabilities	(46,588		)
	Deferred revenue	(80,239		)
	Noncurrent deferred tax liabilities	(149,364		)
	Net assets acquired	425,063
	Goodwill on acquisition	824,339
	Net consideration paid in cash	$	1,249,402
	The fair values of computer hardware and other property, developed technology and contents, other identifiable assets, deferred revenues and its related deferred income tax effect were adjusted following the preliminary valuations by third party valuation firms. Current liabilities were adjusted based on management’s review of underlying reconciliation and supporting data in respect of certain account balances.
	Accounts receivable, accounts payable, and other current assets and liabilities were stated at historical carrying values, given their short-term nature. Other noncurrent assets and liabilities outstanding as of the effective date of the Acquisition have been attributed based on management’s judgments and estimates.
	The Company engaged a third party valuation firm to assist in determining the fair values of computer hardware and other property, developed technology and content, and other identifiable intangible assets acquired, including trademarks and trade names, customer relationships and deferred revenue.
	Computer hardware and other property have been valued using a cost approach based on current replacement and/or reproduction cost of the asset as new, less depreciation attributable to physical, functional, and economic factors.
	Developed technology and content have been valued using the relief from royalty method under the income approach to determine the estimated reasonable royalty rates for each reporting unit based on the comparable royalty agreements. The royalty rates, net of tax, were applied to projected revenues to determine the after-tax royalty cash savings discounted to present value.
	Trademarks and trade names have been valued using the relief from royalty method under the income approach to estimate the cost savings that accrue to the Company which would otherwise have gone to pay royalties or license fees on revenues earned through the use of the asset. Using this approach, trademarks and trade names were valued at $86.2 million, with the estimated useful lives of the Payer, Hospitals and Clinicians trademarks and trade names estimated to be 15 years each.
	Customer relationships were determined using an income approach, taking into account the expected revenue growth and attrition rates of the customers and the estimated capital charges for the use of other net tangible and identifiable net intangible assets. Using this approach, customer relationships were assigned a value of $329.8 million, with the estimated useful lives of the Payer, Hospitals and Clinicians customer relationships estimated to be 11 to 12 years each.
	Deferred revenue has been valued using a cost build-up approach and is calculated as the cost to fulfill the legal performance obligation plus a reasonable profit margin.
	Deferred income tax assets and liabilities as of the Acquisition date represent the expected future tax consequences of temporary differences between the fair values of the assets acquired and liabilities assumed and their tax bases.
	The goodwill recognized upon closing of the Acquisition is attributable mainly to the skill of the acquired work force and Truven’s position as a provider of healthcare data and analytics solutions and services to key constituents of the U.S. healthcare system. The total non tax deductible goodwill relating to the Acquisition is $465.6 million. The total tax deductible goodwill relating to the Acquisition is $358.7 million, which comprises $129.9 million related to the asset purchase and $228.8 million attributable to the historical basis of Thomson Reuters Healthcare.
	The following unaudited pro forma financial data summarizes the Company’s results of operations for the years ended December 31, 2012 and 2011 had the Acquisition occurred as of the beginning of the comparable prior year:
			Years ended December 31,
			2012			2011
	Revenues, net		$	490,625		$	435,918
	Net loss		(11,173		)	(52,462		)
	TRHI did not make any acquisitions in 2011.

Trade_and_other_receivables_No

Trade and other receivables (Notes)	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Trade and other receivables	'
	Trade and other receivables
	Trade and other receivables consisted of the following:
		December 31, 2013			December 31, 2012
	Trade receivables, gross	$	99,011		$	106,699
	Less: Allowance for doubtful accounts	(1,530		)	(1,865		)
	Trade receivables, net	97,481			104,834
	Other receivables	317			307
	Trade and other receivables, net	$	97,798		$	105,141
	Other receivables includes notes receivable from Holdings LLC, the direct parent company of the Company. The notes receivable bear interest at a rate per annum of 1.9%. Interest is payable in arrears on each October 15, commencing on October 15, 2014. In lieu of paying in cash for the interest payments, any accrued but unpaid interest shall be capitalized and added as of such interest payment date to the principal amount of the note receivable. At any time, Holdings LLC may redeem all or any part of the note receivable at a redemption price equal to 100% of the principal amount redeemed plus all interest accrued and unpaid through the redemption date.

Prepaid_and_other_current_asse

Prepaid and other current assets (Notes)	12 Months Ended
	Dec. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Prepaid and other current assets	'
	Prepaid and other current assets
	Prepaid expenses and other current assets consisted of the following:
		December 31, 2013		December 31, 2012
	Royalties	$	3,502	$	3,559
	Commissions and distribution fees	9,046		5,618
	Services, licenses and maintenance	10,720		8,388
	Others	940		844
	Prepaid expenses and other current assets	$	24,208	$	18,409

Computer_hardware_and_other_pr

Computer hardware and other property (Notes)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Computer hardware and other property	'
	Computer hardware and other property
	Computer hardware and other property, net, consisted of the following:
		December 31, 2013
		Computer hardware			Building and leasehold improvements			Furniture, fixtures and equipment			Total
	Computer hardware and other property, gross	$	67,285		$	5,166		$	2,861		$	75,312
	Accumulated depreciation	(24,762		)	(1,124		)	(1,389		)	(27,275		)
	Computer hardware and other property, net	$	42,523		$	4,042		$	1,472		$	48,037
		December 31, 2012
		Computer hardware			Building and leasehold improvements			Furniture, fixtures and equipment			Total
	Computer hardware and other property, gross	$	40,494		$	3,106		$	3,425		$	47,025
	Accumulated depreciation	(5,929		)	(393		)	(512		)	(6,834		)
	Computer hardware and other property, net	$	34,565		$	2,713		$	2,913		$	40,191

Developed_technology_and_conte

Developed technology and content (Notes)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Developed technology and content	'
	Developed technology and content
	Developed technology and content, net, consisted of the following:
		31-Dec-13			31-Dec-12
	Developed technology and content, gross	$	195,961		$	175,828
	Accumulated amortization	(47,324		)	(15,493		)
	Developed technology and content, net	$	148,637		$	160,335

Goodwill_Notes

Goodwill (Notes)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill	'
	Goodwill
	Balances and changes in the carrying amount of goodwill for the year December 31, 2013 and the Successor Period ended December 31, 2012 were as follows:
		Payer			Hospitals			Clinicians			Total
	Balance as of April 20, 2012	$	—		$	—		$	—		$	—
	Acquisition (see Note 3)	414,992			206,312			203,035			824,339
	Balance as of December 31, 2012	414,992			206,312			203,035			824,339
	Impairment charge	(207,918		)	(65,792		)	(92,952		)	(366,662		)
	Balance as of December 31, 2013	$	207,074		$	140,520		$	110,083		$	457,677
	Goodwill is not amortized. Instead, goodwill is tested for impairment annually as well as whenever there is an indication that the carrying amount may not be recoverable. The goodwill arising from the Acquisition (see Note 3) has been allocated to the Company's reporting units, which also represents the Company's operating and reportable segments.
	The Company performed its annual goodwill impairment test on November 1, 2013. The fair value of the Company’s reporting units was estimated primarily using a combination of the income approach and the market approach. The Company used discount rates ranging from 11.6% to 13.4% in determining the discounted cash flows for each of our reporting units under the income approach, corresponding to our cost of capital, adjusted for risk where appropriate. In determining estimated future cash flows, current and future levels of income were considered that reflected business trends and market conditions. Under the market approach, the Company estimated the fair value of the reporting units based on peer company multiples of earnings before interest, taxes, depreciation and amortization (EBITDA). The Company also considered the multiples at which businesses similar to the reporting units have been sold or offered for sale. The combined income approach and market approach to determine the fair value of each reporting unit received a weighted percentage of 70% and 30%, respectively.
	The first step of the Company’s impairment test indicated that the carrying value of all the three reporting units exceeded its fair value due to lower-than-expected growth in revenue and cash flow in fiscal year 2013 resulting from certain selling cycle delays, particularly in the government sector, uncertainty in the healthcare sector related to the Patient Protection and Affordable Care Act, higher-than-expected costs due to significant investments in technology infrastructure, as well as an increase in the discount rate used in the discounted cash flow analysis as compared to the rate used in the prior year’s analysis.
	The second step of the goodwill impairment test required us to fair value all assets and liabilities of our three reporting units to determine the implied fair value of each reporting unit’s goodwill. We compared the implied fair value of each reporting unit’s goodwill to its carrying value. This test resulted in an aggregate non-cash goodwill impairment charge of $366.7 million in the fourth quarter of 2013.

Other_identifiable_intangible_

Other identifiable intangible assets (Notes)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Other identifiable intangible assets	'
	Other identifiable intangible assets
	Other identifiable intangible assets, net, consisted of the following:
		December 31, 2013
		Average life (years)	Cost		Accumulated amortization			Net
	Customer relationships	11.5	$	329,800	$	(44,983	)	$	284,817
	Trademarks and trade names	15	86,200		(9,003		)	77,197
			$	416,000	$	(53,986	)	$	362,014
		December 31, 2012
		Average life (years)	Cost		Accumulated amortization			Net
	Customer relationships	11.5	$	329,800	$	(16,270	)	$	313,530
	Trademarks and trade names	15	86,200		(3,257		)	82,943
			$	416,000	$	(19,527	)	$	396,473
	Customer relationships represent corporate customer contracts and customer relationships arising from such contracts with the majority of revenues recurring year over year.
	Trade names include Advantage Suite, Care Discovery, Micromedex, among many of the Company’s product names and brand logos recognized in the U.S. market.
	At December 31, 2013, estimated future amortization expense for each of the next five years is $34.5 million.

Accounts_payable_and_accrued_e

Accounts payable and accrued expenses (Notes)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accounts payable and accrued expenses	'
	Accounts payable and accrued expenses
	Accounts payable and accrued expenses consisted of the following:
		December 31, 2013		December 31, 2012
	Accounts payable - trade	$	26,259	$	48,691
	Accrued employee compensation	13,529		23,953
	Accrued royalties	3,773		3,793
	Accrued professional fees	4,409		8,658
	Accrued interest	2,966		3,367
	Customer deposits	618		806
	Other accrued expenses	1,822		3,239
	Accounts payable and accrued expenses	$	53,376	$	92,507

Longterm_Debt_Notes

Long-term Debt (Notes)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Long-Term Debt	'
	Long-Term Debt
	The Company's long-term debt consists of the following:
		December 31, 2013		December 31, 2012
	Senior Credit Facility
	Term Loan Facility (net of $14,156 and $12,174 discount, respectively)	$	516,831	$	512,813
	Revolving Credit Facility	30,000		—
	10.625% Senior Notes ("the Notes") (net of $1,723 and $1,991 discount, respectively)	325,427		325,159
		872,258		837,972
	Less: current portion of long-term debt	5,350		5,276
	Long-term debt	$	866,908	$	832,696
	In connection with the Acquisition, on June 6, 2012, Truven entered into the Senior Credit Facility and issued the 10.625% Senior Notes ("Notes"). Except as otherwise indicated by the context, the Old Notes and the Exchange Notes are collectively and individually defined as the "Notes".
	Senior Credit Facility
	The Senior Credit Facility, as amended on April 26, 2013, is with a syndicate of banks and other financial institutions and provides financing of up to $585.0 million, consisting of the $535.0 million Term Loan Facility with a maturity of seven years and the $50.0 million Revolving Credit Facility with a maturity of five years. As of December 31, 2013, the Company has an outstanding revolving loan of $30.0 million and outstanding letters of credit amounting to $0.3 million, which, while not drawn, reduce the available line of credit under the Revolving Credit Facility to $19.7 million.
	Borrowings under the Senior Credit Facility, other than swing line loans, bear interest at a rate per annum equal to an applicable margin plus, at Truven’s option, either (a) a base rate determined by reference to the highest of (1) the prime rate of JPMorgan Chase Bank, N.A., (2) the federal funds effective rate plus 0.50% and (3) the one month Eurodollar rate plus 1.00%; provided, that the base rate for the Term Loan Facility at any time shall not be less than 2.25%, or (b) a Eurodollar rate adjusted for statutory reserve requirements for a one, two, three or six month period (or a nine or twelve month interest period if agreed to by all applicable lenders); provided that the Eurodollar base rate used to calculate the Eurodollar rate for the Term Loan Facility at any time shall not be less than 1.25%. Swing line loans will bear interest at the interest rate applicable to base rate loans, plus an applicable margin. In addition to paying interest on outstanding principal under the Senior Credit Facility, we are required to pay a commitment fee to the lenders under the Revolving Credit Facility in respect of the unutilized commitments thereunder at a rate equal to 0.50% (subject to reduction upon attainment of certain leverage ratios). We will also pay customary letter of credit fees and certain other agency fees. Truven may voluntarily repay outstanding loans under the Senior Credit Facility at any time without premium or penalty, other than customary “breakage” costs with respect to adjusted LIBOR loans. We are required to repay $1.3 million of the Term Loan Facility quarterly, through March 31, 2019, with any remaining balance due June 6, 2019.
	All obligations under the Senior Credit Facility are guaranteed by the Company and each of Truven’s future wholly-owned domestic subsidiaries (of which there are currently none). All obligations under the Senior Credit Facility and the guarantees of those obligations are collateralized by first priority security interests in substantially all of Truven’s assets as well as those of each guarantor (subject to certain limited exceptions).
	The Senior Credit Facility contains a number of covenants that, among other things, restrict, subject to certain exceptions, Truven’s ability and the ability of each of any restricted subsidiaries: to sell assets, incur additional indebtedness, prepay other indebtedness (including the Notes), pay dividends and distributions or repurchase its capital stock, create liens on assets, make investments, make certain acquisitions, engage in mergers or consolidations, engage in certain transactions with affiliates, amend certain charter documents and material agreements governing subordinated indebtedness, change the business conducted by it and its subsidiaries, and enter into agreements that restrict dividends from subsidiaries.
	In addition, the Senior Credit Facility requires Truven to comply with a quarterly maximum consolidated senior secured leverage ratio provided for in the Senior Credit Facility as long as the commitments under the Revolving Credit Facility remain outstanding (subject to certain limited exceptions). The Senior Credit Facility also contains certain customary representations and warranties, affirmative covenants and events of default. As of December 31, 2013, the Company was in compliance with all of these credit facility covenants.
	Refinancing
	On October 3, 2012, we entered into the First Amendment to the Senior Credit Facility with a syndicate of banks and other financial institutions with no changes in the terms and conditions other than the reduction of the applicable margin by 1.00%. The loans with certain lenders had been determined to be extinguished under FASB ASC Topics 470-50, Modifications and Extinguishments. As a result, the Company recorded a loss on early extinguishment on certain debt amounting to $6.7 million in 2012, representing unamortized debt discount, unamortized debt issue costs and certain costs related to the extinguished debt. The loss on early extinguishment of debt is included in interest expense in the consolidated comprehensive loss.
	Truven incurred lenders fees of $6.7 million, mainly consisting of call or premium fees in connection with this transaction. Of the $6.7 million, $5.2 million had been recorded as part of original issue discount and was presented as net of debt in the consolidated balance sheet of the Company. The remaining lenders fee of $1.5 million related to the debt extinguished has been expensed as part of interest expense in the consolidated comprehensive loss and was presented under cash flows from operating activities in the Company’s consolidated statement of cash flows.
	On April 26, 2013, we entered into the Second Amendment to the Senior Credit Facility (referred to as the "April 2013 Refinancing") with a syndicate of banks and other financial institutions to (i) increase the aggregate principal amount of the Term Loan Facility from $523.7 million to $535.0 million, (ii) reduce the applicable margin by 1.25%, (iii) with respect to the Term Loan Facility, determine the applicable margin in accordance with a pricing grid based on our consolidated total leverage ratio following delivery of financial statements at the end of each fiscal year or quarter, as applicable, after the second quarter of fiscal year 2013, (iv) revise the quarterly principal payments from $1,319.0 to $1,337.5 starting in June 30, 2013 and (v) extend the 1% repricing call protection from June 6, 2013 to October 26, 2013. There were no other changes in the terms and conditions. The loans with certain lenders in the bank syndicate had been determined to be extinguished under FASB ASC Topics 470-50, Modifications and Extinguishments. As a result, the Company recorded a loss on early extinguishment on certain debt amounting to $3.3 million during the period, representing unamortized debt discount, unamortized debt issue costs and certain costs related to the extinguished debt. The loss on early extinguishment of debt is included in interest expense in the consolidated comprehensive loss.
	In connection with the April 2013 Refinancing, the Company incurred lenders' fees of $6.7 million, representing call premium. Of the $6.7 million, $5.8 million was recorded as part of original issue discount and presented as net of debt in the consolidated balance sheet as of December 31, 2013. Other third party costs of $0.1 million, representing legal costs, were recorded as an expense for the period ended December 31, 2013.
	The remaining lenders' fees of $0.9 million related to the debt extinguished has been expensed as part of interest expense in the condensed consolidated statement of comprehensive loss for the year ended December 31, 2013 and is presented under cash flows from operating activities in the Company’s consolidated statement of cash flows for year ended December 31, 2013.
	On February 14, 2014, the Company repaid $15 million of principal amount plus interest drawn against the Revolving Credit Facility.
	10.625% Senior Notes due 2020
	The Notes, which were issued under an indenture, dated June 6, 2012 ( the “Indenture”, as supplemented by the First Supplemental Indenture, whereby Truven became a party to the Indenture as successor in interest to Wolverine, and the Second Supplemental Indenture referred to below), with The Bank of New York Mellon Trust Company, N.A. as trustee, bear interest at a rate of 10.625% per annum, payable on June 1 and December 1 of each year (commencing on December 1, 2012), and have a maturity date of June 1, 2020.
	The Notes are general unsecured senior obligations of Truven, fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis by the Company and each of Truven’s existing and future wholly-owned domestic restricted subsidiaries (of which there currently are none) that is a borrower under or that guarantees the obligations under the Senior Credit Facility or any other indebtedness of Truven or any other guarantor.
	Truven may redeem some or all of the Notes at any time prior to June 1, 2016 at 100% of the principal amount thereof plus the applicable premium pursuant to the Indenture as of the applicable redemption date, plus accrued and unpaid interest and any additional interest to, but excluding, the applicable redemption date. Truven may redeem some or all of the Notes at any time on or after June 1, 2016 at 105.313% of the principal amount thereof, declining ratably to 100% of the principal amount thereof on or after June 1, 2018, plus, in each case, accrued and unpaid interest and any additional interest to, but excluding, the applicable redemption date. In addition, at any time prior to June 1, 2015, Truven (subject to certain conditions) may redeem up to 35% of the aggregate principal amount of the Notes using net cash proceeds from certain equity offerings at 110.625% of the aggregate principal amount of the Notes plus accrued and unpaid interest and any additional interest, to, but excluding, the applicable redemption date. If Truven experiences a change of control (as defined in the Indenture), it will be required to make an offer to repurchase the Notes at a price in cash equal to 101% of the aggregate principal amount thereof, plus accrued and unpaid interest, and any additional interest, to, but excluding, the date of purchase.
	The Indenture contains covenants limiting Truven and its restricted subsidiaries with respect to other indebtedness, investments, liens, dividends, purchases or redemptions of stock, transactions with affiliates and mergers and sales of assets. The Indenture also contains covenants limiting the ability of wholly-owned restricted subsidiaries to guarantee payment of any indebtedness of Truven or any subsidiary guarantor and limiting the Company’s business and operations. We were in compliance with all of these covenants as of December 31, 2013.
	On June 5, 2013, we entered into the second supplemental indenture (the “Second Supplemental Indenture”), whereby the guarantee release provision in Section 10.2(d)(1)(B) of the Indenture, which allows guarantors to be released from their obligations under the Indenture upon the release or discharge of such guarantor’s guarantee of the Senior Credit Facility or the guarantee which resulted in the creation of the guarantee under the Indenture (subject to certain limitations), was amended to apply only to subsidiary guarantors and not to Truven Holding.
	Pursuant to a registration rights agreement dated June 6, 2012, we agreed (i) to use commercially reasonable efforts to file with the Securities and Exchange Commission (the "SEC") an exchange offer registration statement pursuant to which we would exchange the Notes issued in a private offering (the "Old Notes") (and related guarantees) for a like aggregate principal amount of new registered notes, which are identical in all material respects to the Old Notes, except for certain provisions, among others, relating to additional interest and transfer restrictions (the "Exchange Notes") (and related guarantees) or (ii) under certain circumstances, to use commercially reasonable efforts to file a shelf registration statement with the SEC with respect to the Old Notes (and related guarantees), in each case by March 3, 2013. We did not file the required registration statement for the Notes by March 3, 2013, and consequently, we were required to pay additional penalty interest of 0.25% per annum for the 90 day period commencing March 4, 2013, and an additional 0.25% with respect to each subsequent 90 day period, in each case until and including the date the exchange offer is completed, up to a maximum increase of 1.00% per annum.
	On June 26, 2013, the exchange offer registration statement was declared effective by the SEC. On July 31, 2013, Truven closed its offer to exchange the Old Notes for the Exchange Notes. The interest rate on the new Exchange Notes reverted to 10.625%.
	As of December 31, 2013, we had incurred and paid additional penalty interest of $463.5.
	As of December 31, 2013, principal maturities of long-term debt for the next five years and thereafter consist of:
	2014	$	5,350
	2015	5,350
	2016	5,350
	2017	35,350
	2018	5,350
	Thereafter	810,158
		$	866,908

Employee_benefit_plans_Notes

Employee benefit plans (Notes)	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Employee benefit plans	'
	Employee benefit plans
	Predecessor
	Prior to the Acquisition, TRHI’s employees participated in various employee benefit plans under the Predecessor Parent as follows:
	Defined contribution plan
	Certain employees of TRHI participated in a defined contribution savings plan administered by the Predecessor Parent under Section 401(k) of the Internal Revenue Code. The plan covered substantially all employees based in the United States who met minimum age and service requirements and allowed participants to defer a portion of their annual compensation on a pre-tax basis. TRHI matched a certain portion of employee contributions, which vested based upon an employee’s years of service and become fully vested after four years of service. Matching contribution expense directly attributable to TRHI’s employees was $3,091 for the Predecessor Period ended June 6, 2012 and $5,747 for the Predecessor Period ended December 31, 2011.
	Predecessor Defined benefit pension plan
	Certain employees of TRHI participated in a defined benefit pension plan sponsored and administered by the Predecessor Parent. The pension plan required benefits to be paid to eligible employees at retirement, based primarily upon years of service and compensation rates near retirement. The expense for TRHI employees who participated in this plan was $159 for the Predecessor Period ended June 6, 2012 and $364 for the Predecessor Period ended December 31, 2011.
	All of the TRHI employees benefit plans’ assets and liabilities are accounted for in the Predecessor Parent’s financial statements. No assets or liabilities are reflected on the Company’s consolidated balance sheets, and pension and other postretirement expenses for the Company have been determined on a multi-employer plan basis. The Predecessor’s combined financial statements for the Predecessor Period ended June 6, 2012, and for the Predecessor Period ended December 31, 2011 included the employee benefit expense allocated to it by the Predecessor Parent for TRHI employees who participated in the benefit plans. The expenses are included in the “Allocation of costs from Predecessor Parent and affiliates” in the combined statements of comprehensive income (loss). Further detail is included in Note 18. Upon consummation of the Acquisition, TRHI employees ceased to participate in the Predecessor Parent’s benefit plans. These employees are still entitled to the benefits that have vested under the plans; however, any subsequent costs or liability of these plans will be borne by the Predecessor Parent.
	Successor
	Following the closing of the Acquisition on June 6, 2012, Truven's employees became eligible to participate in new 401(K) defined contribution plan sponsored by Truven. Under the plan, employees may contribute a percentage of compensation and Truven will match a portion of the employees’ contribution. Truven’s contribution to the plan for the year ended December 31, 2013 and Successor Period from April 20, 2012 to December 31, 2012 amounted to $6,975 and $3,294, respectively. Truven does not offer any defined benefit plan, post-retirement healthcare benefit plan or deferred compensation plan.

Sharebased_Compensation_Notes

Share-based Compensation (Notes)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Share-based Compensation	'
	Share-based Compensation
	Under its stock incentive plan, the Predecessor Parent may grant stock options, Time-Based Restricted Share Units (“TRSUs”), Performance Restricted Share Units (“PRSUs”) and other awards to certain employees up to a maximum of 50,000,000 common shares. The Predecessor Parent had 19,292,115 awards available for grant in 2011.
	Apart from allocated share-based expenses as discussed in Note 18, TRHI recognized share-based compensation expense on its stock incentive plan of $2,519 for the Predecessor Period ended June 6, 2012 and $1,105 for the year ended December 31, 2011. The total associated tax benefits recognized were $972 for the Predecessor Period ended June 6, 2012, and $441 for the year ended December 31, 2011.
	In connection with the Acquisition, any unvested share-based payments held by TRHI employees became fully vested or had vested on a pro-rata basis in proportion to the performance period that ended at the date of the Acquisition. TRHI employees were given six months from the date of the closing of the Acquisition during which to exercise the options. The compensation expense of $2,519 includes $1,464 to accelerate vesting. Therefore, as of June 6, 2012, all outstanding options held by TRHI employees were exercisable.
	For all share-based payment awards, the expense recognized was adjusted for estimated forfeitures where the service was not expected to be provided. Estimated forfeiture rates were developed based on the analysis of historical forfeiture data. The estimated forfeitures are adjusted to income when the share-based payment awards are fully vested.
	The following table summarizes the valuation methods used to measure fair value for each type of award and the related vesting period over which compensation expense is recognized:
	Type of award	Vesting period	Fair value measure	Compensation
				expense based on
	Stock options	Up to four years	Black-Scholes option pricing model	Fair value on business day prior to grant date
	TRSUs	Up to seven years	Closing Common share price	Fair value on business day prior to grant date
	PRSUs	Three year performance period	Closing Common share price	Fair value on business day prior to grant date
	Stock options
	The maximum term of an option is 10 years from the date of grant. Under the plan, options were granted by reference to the Predecessor Parent’s common share price on the NYSE or TSX, respectively.
	The weighted average fair value of options granted and principal assumptions used in applying the Black-Scholes option pricing model were as follows:
		Predecessor
		January 1, 2012 to June 6, 2012	2011
	Weighted average grant date fair value	5.21	8.42
	Weighted average of key assumptions
	Exercise price	28.42	38.98
	Risk-free interest rate	1.20%	2.70%
	Dividend yield	3.40%	3.30%
	Volatility factor	28%	29%
	Expected life (in years)	6	6
	The Black-Scholes model was developed for use in estimating the fair value of traded options that have no vesting restrictions. The model requires the use of subjective assumptions, including expected stock price volatility; historical data has been considered in setting the assumptions.
	During the Predecessor Period ended June 6, 2012, no options were exercised. There were 4,230 options exercised in 2011. The amount of cash received by the Predecessor Parent from the exercise in 2011was $113. The total fair value of options vested was approximately $2,725 and $85 and as of June 6, 2012 and December 31, 2011, respectively.
	Transactions related to the Predecessor Parent’s stock options in the Predecessor Period ended June 6, 2012 and the year ended December 31, 2011 are summarized as follows:
		Shares		Weighted			Weighted		Aggregate
				average			average		intrinsic value
				exercise			remaining		(in thousands)
				price			term
							(in years)
	Outstanding at December 31, 2011	270,753		$	34.16		7.38		$	182
	Granted	90,520		28.42			—		—
	Outstanding and exercisable at June 6, 2012	361,273		$	32.71		0		$	280
	Time-based restricted share units
	TRSUs gave the holder the right to receive one common share of the Predecessor Parent’s stock for each unit that vested on the vesting date. The holders of TRSUs had no voting rights, but accumulate additional units based on notional dividends paid by the Predecessor Parent on its common shares at each dividend payment date, which were reinvested as additional TRSUs. The total fair value of TRSUs vested was approximately $1,061 and $2,381as of June 6, 2012 and December 31, 2011, respectively.
	In connection with the Acquisition, TRSUs held by TRHI employees became vested.
	Performance restricted share units
	PRSUs gave the holder the right to receive one common share of the Predecessor Parent’s stock for each unit that vested on the vesting date. The holders of PRSUs had no voting rights, but accumulated additional units based on notional dividends paid by the Predecessor Parent on its common shares at each dividend payment date, which were reinvested as additional PRSUs. The percentage of PRSUs initially granted that vested depended upon the Predecessor Parent’s performance over a three-year performance period as measured against pre-established performance goals. Between 0% and 200% of the initial amounts may have vested for grants made from 2009 through 2011. The total fair value of PRSUs vested was approximately $3,220 and $231 as of June 6, 2012 and December 31, 2011, respectively.
	In connection with the Acquisition, PRSUs held by TRHI employees became vested in proportion to the performance period that ended.
	Transactions related to TRSUs and PRSUs in 2012 and 2011 are summarized as follows:
		TRSU				PRSU
		Shares		Weighted		Shares		Weighted
				average				average
				grant-date				grant-date
				fair value				fair value
	Outstanding at December 31, 2011	28,748		36.75		148,949		31.77
	Dividends accrued	110		—		1,138		—
	Granted	—		—		67,740		28.42
	Vested	(24,829	)	36.48		(41,016	)	23.46
	Vested (accelerated)	(4,029	)	38.55		(63,834	)	35.37
	Forfeited or expired	—		—		(112,977	)	31.13
	Outstanding at June 6, 2012	—		—		—		—
	Employee stock purchase plan (“ESPP”)
	The Predecessor Parent maintained an employee stock purchase plan whereby eligible employees could purchase common shares of the Predecessor Parent at a 15% discount up to a specified limit utilizing after-tax payroll deductions. The discount was expensed as incurred was $139, for the Predecessor Period ended June 6, 2012 and $298 for the period ended December 31, 2011.
	Following the closing of the Acquisition on June 6, 2012, Truven has no share-based payment plan related to the plans administered by our Predecessor.
	Successor
	In October 2012, the Company’s immediate parent, Holdings LLC, established a compensation award in accordance with the Operating Agreement to provide Class B Membership Interests in Holdings LLC to certain executive officers of the Company, up to 6.25% in the aggregate. The membership interests will vest 20% on each of the first five anniversaries of June 6, 2012, so that 100% of each awardee's outstanding Class B Membership Interests will vest on June 6, 2017 subject to certain conditions. In addition, 100% of each Class B Membership Interests may vest in certain circumstances in connection with a change in control as defined in the Operating Agreement.
	Each Class B Membership Interest represents the right to receive a percentage of the distributions made by Holdings LLC when such distributions are actually made and such distributions exceed specified internal rates of return thresholds. There are transfer restrictions on the Class B Membership Interests and the executive officers would forfeit the unvested interest upon termination of employment. A summary of the Class B Membership Interests is as follows:
		Ownership interest (%)		Fair value at grant date
	Balance at December 31, 2012	4.1		$	5,714
	Granted	0.9		1,162
	Forfeited	(0.4	)	(502		)
Balance at December 31, 2013	4.6		$	6,374
Outstanding and vested as of December 31, 2013	0.8		$	1,143
The fair value at the date of grant was based upon the value of the Class B Membership Interests of Holdings LLC less a marketability discount since there is no active market to trade Class B Membership Interests. The marketability discount was determined using a geometric average rate put option model and a Black-Scholes put option model using the expected term, risk-free rate, and volatility for liquidity terms. The value was determined as of the grant date based upon a number of factors, including the amount of investment made in exchange for Class B Membership Interests of Holdings LLC by Veritas Capital and certain members of management of the Company.
The Company recognized compensation expense against additional paid in capital of $1,457 and $329, net of an estimated forfeiture rate of 10%, for the year ended December 31, 2013 and for the Successor Period from April 20, 2012 to December 31, 2012, respectively, which is recorded in General and administrative expense in the Company’s consolidated statements of comprehensive loss.
The total unrecognized compensation cost related to unvested Class B Membership Interests expected to be recognized over the next 3.5 years is $4,062.
As of December 31, 2013, 0.8% of the Class B Membership Interests has vested with the estimated fair value of $1,121.

Other_Operating_Expenses_Notes

Other Operating Expenses (Notes)	12 Months Ended
	Dec. 31, 2013
Other Income and Expenses [Abstract]	'
Other Operating Expenses	'
	Other Operating Expenses
	The components of other operating expenses include the following:
		Year ended December 31,		From inception (April 20, 2012) to December 31,		January 1, 2012 to June 6,		Year ended December 31,
		2013		2012		2012		2011
		Successor				Predecessor
	Disposal related costs	$	—	$	—	$	9,818	$	12,560
	Severance and retention bonuses	3,808		10,184		7,741		6,768
	Acquisition related costs	27,007		37,980		—		460
	Asset write-offs (see Note 16)	1,294		—		—		—
	Other	2,929		1,458		1,244		214
	Total other operating expenses	$	35,038	$	49,622	$	18,803	$	20,002
	Predecessor
	Disposal related costs in the Predecessor Period are primarily comprised of audit services, accounting and consulting services and legal fees related to TRUSI's disposal of the Thomson Reuters Healthcare business. Severance and retention bonuses in the Predecessor Period include severances of employees in connection with the planned disposal of TRHI.
	Prior to the Acquisition, on March 31, 2012, the Predecessor Parent entered into a retention agreement (the “Retention Agreement”) with key TRHI employees in conjunction with the disposal of the business. Pursuant to the Retention Agreements, the Predecessor Parent agreed to provide for retention and bonus payment to certain employees based on a percentage of salary and targeted transaction price, respectively. The payment was contingent upon the employees continuing services to the buyer after the Acquisition for periods ranging from 90 days to one year. Although the Predecessor Parent retained the legal and contractual obligation to pay the employees, the compensation expense was recorded in the period when the service was performed and was allocated in proportion to the days of service in both Predecessor and Successor Periods. As a result, for the period from April 1, 2012 to June 6, 2012, (Predecessor) TRHI recorded $5.8 million of retention and bonuses expense against Net Investment of Predecessor Parent. The compensation which was paid by Predecessor Parent was deemed an investment contribution.
	Successor
	Acquisition related costs include costs incurred related to technology and other costs in connection with the Company's transition into a standalone business. For the year ended December 31, 2013, acquisition related costs included $12.9 million of expenses incurred mainly as a result of separating our IT infrastructure from Predecessor Parent, $9.2 million of costs related to the transitional services agreement with Thomson Reuters, and $4.9 million related to rebranding, consulting and other professional fees. For the Successor Period from April 20, 2012 to December 31, 2012, acquisition related costs consisted of $12.0 million of transaction fees to the Sponsor, and $26.0 million of direct acquisition costs consisting of legal, finance, consulting and professional fees.
	Severance and retention bonuses primarily relate to the Acquisition of TRHI. As discussed above, prior to the Acquisition, on March 31, 2012, the Predecessor Parent entered into Retention Agreements with key TRHI employees in conjunction with the disposal of the business. The compensation expense was recorded in the period when the service was performed and was allocated in proportion to the days of service in both Predecessor and Successor Periods. For the year ended December 31, 2013 and the Successor Period from April 20, 2012 to December 31, 2012, Truven recorded $1.4 million and $8.6 million of retention and bonus expense, respectively, against Additional Paid In Capital in the Equity section of the consolidated balance sheet. The compensation paid by Predecessor Parent on behalf of Truven was deemed a capital contribution.
	The Sponsor advisory fees are included in other expenses and represent fees paid to the Sponsor under the advisory agreement the Company entered into with the Sponsor in connection with the Acquisition (see Note 18).

Income_Taxes_Notes

Income Taxes (Notes)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	For income tax purposes, the Predecessor’s income or loss was included in the Predecessor Parent’s individual and combined tax returns that include the Thomson Reuters Healthcare business as required within each jurisdiction. For the period subsequent to the Acquisition, the Company files a consolidated federal tax return. The provision for income taxes in the consolidated and combined statements of comprehensive income (loss) reflects income taxes as if the businesses were standalone entities and filed separate income tax returns.
	The components of income tax expense are as follows:
		Successor								Predecessor
		Year ended			From inception (April 20, 2012) to December 31, 2012					January 1, 2012 to June 6,			Year ended
		December 31,								2012			December 31,
		2013											2011
	Current
	Federal	$	—		$	—				$	(4,807	)	$	3,174
	State	235			82					(539		)	801
	Foreign	236			—					—			—
		471			82					(5,346		)	3,975
	Deferred
	Federal	(75,817		)	(26,189		)			477			5,353
	State	(9,472		)	(3,886		)			66			531
	Foreign	(109		)	—					—			—
		(85,398		)	(30,075		)			543			5,884
	Total (benefit from) provision for income taxes	$	(84,927	)	$	(29,993	)			$	(4,803	)	$	9,859
	The tax effects of the significant components of temporary differences giving rise to the Company’s deferred income tax assets and liabilities are as follows:
		December 31,					December 31,
		2013					2012
	Allowance for doubtful accounts and other reserves	$	597				$	713
	Transaction costs	—					468
	Net operating loss and tax credit carry-forwards	74,616					33,942
	Prepaid expenses	1,094					2,618
	Accrued expenses	—					4,789
	Deferred revenue	—					4,002
	Goodwill	42,726					—
	Deferred rent	1,121					—
	Other	1,197					575
	Total deferred tax assets	121,351					47,107
	Other identifiable intangible assets	(125,652		)			(134,097		)
	Goodwill	—					(7,049		)
	Trade and other receivables	(2,224		)			(1,478		)
	Debt exchange	(5,585		)			—
	Other long-lived assets	(10,406		)			(12,510		)
	Other	(222		)			—
	Total deferred tax liabilities	(144,089		)			(155,134		)
	Net deferred tax liabilities	$	(22,738	)			$	(108,027	)
	The deferred tax assets and liabilities are classified in the consolidated and combined balance sheets based on the balance sheet classification of the related assets and liabilities. Deferred tax assets and liabilities are shown net of one another if they are in the same jurisdiction. The components of the net deferred tax liabilities as reported on the consolidated balance sheets are as follows:
		December 31,				December 31,
		2013				2012
	Current deferred tax asset	$	—			$	10,648
	Current deferred tax liabilities	(711		)		—
	Noncurrent deferred tax liabilities	(22,027		)		(118,675		)
	Net deferred tax asset (liabilities)	$	(22,738	)		$	(108,027	)
	Pursuant to the Stock and Asset Purchase Agreement, the Predecessor Parent has provided an indemnity for all tax liabilities that relate to periods prior to June 7, 2012, including any taxes assessed that are directly attributable to cash received by the Predecessor Parent, but only if and to the extent such taxes result in an increase in cash taxes actually paid by Truven in any Successor tax period.
	The Company assesses the realization of its deferred tax assets and the need for a valuation allowance on a standalone basis. The assessment requires judgment on the part of management with respect to benefits that could be realized from future taxable income, as well as other positive and negative factors influencing the realization of deferred tax assets. As of December 31, 2013, the Company determined that it will more likely than not realize its deferred tax assets. Federal and state net operating loss (“NOL”) carry forwards at December 31, 2013 were $186.8 million and $171.7 million, respectively. The federal NOL carry forward starts to expire in 2032. The state NOL carry forwards start to expire in 2014. Certain state NOL’s are subject to the limitation rule in accordance with Section 382 of the Internal Revenue Code.
	A reconciliation of the statutory U.S. federal income tax rate to the Company’s effective tax rate is as follows:
		Successor				Predecessor
		Years ended December 31, 2013	From inception (April 20, 2012) to December 31, 2012			January 1, 2012 to June 6, 2012	Years ended December 31, 2011
	Income taxes at federal statutory rate	35.00%	35.00%			35.00%	35.00%
	State and local tax	2.1	3			3.2	4
	Foreign rate differential	0.1	—			—	—
	State rate changes	-0.7	—			—	—
	Non-deductible transaction expenses	—	-2			—	—
	Goodwill impairment charge	-17	—			—	—
	Research tax credit	0.2	—			—	-0.7
	Other permanent items	—	-0.3			0.4	1.6
	Effective rate	19.70%	35.70%			38.60%	39.90%

Commitment_and_Contingencies_N

Commitment and Contingencies (Notes)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitment and Contingencies
	Leases
	Operating Leases
	The Company occupies certain facilities and uses operating equipment under noncancelable operating lease arrangements expiring at various dates through 2021. Future minimum lease payments under these operating leases are as follows:
	For the period ending December 31,
	2014	$	10,600
	2015	9,928
	2016	9,258
	2017	5,250
	2018	4,314
	Thereafter	9,790
		$	49,140
	Rent expense was $11.1 million, $4.2 million, $5.9 million and $9.5 million for the period ended December 31, 2013, period from January 1, 2012 to June 6, 2012, period from April 20, 2012 to December 31, 2012, and period ended December 31, 2011, respectively.
	Capital Leases
	During 2013, the Company entered into certain computer hardware lease arrangements that are classified as capital leases. The net book value of the computer hardware classified as capital leases included in the computer hardware and other property account in the balance sheet amounted to $4.1 million, net of accumulated depreciation of $0.4 million.
	Future minimum lease payments under these capital leases are as follows:
	For the period ending December 31,
	2014	$	1,731
	2015	759
	2016	759
	2017	759
	2018 and thereafter	—
	Total future minimum lease payments	$	4,008
	Less imputed interest	309
	Present value of future minimum lease payments	$	3,699
	Security and Guarantee Agreements
	The Company has entered into guarantee and security arrangements in respect of its indebtedness as described in Note 11.
	Contractual Commitments
	Revenue Sharing Agreement
	Effective January 1, 2013, the Company modified its agreement with a supplier under which it markets and licenses to its customers a private label version of the supplier's platform solution in conjunction with the Company's health information applications. The agreement contains a revenue share arrangement based on net revenue targets. The supplier's revenue share percentage is guaranteed by the Company in the minimum amounts of $2 million, $4 million and $6 million, for the calendar years 2013, 2014 and 2015, respectively. The guaranteed revenue share is paid in advance by the Company on March 1st of each calendar year and is applied against the revenue share of the supplier earned through March 1st of the following calendar year. The agreement provides a grace period for the Company of up to August 31st of the following calendar year in the event that the supplier's revenue share earned does not reach the prepayment amount. After the grace period, if the revenue share earned does not meet the minimum target then the entire prepayment amount is deemed earned by the supplier. As of December 31, 2013, the balance remaining from the $2 million that was paid in 2013 amounted to $0.7 million, net of $1.3 million amount written off representing the estimated revenue share of the supplier that will not be met on grace period.
	Litigation and Legal Proceedings
	Truven has been named as a defendant in approximately 225 separate pharmaceutical tort lawsuits relating to the use of Reglan or its generic version, the first of which was filed in June 2010 and the rest of which were filed in March 2012. All of these actions are pending in the Court of Common Pleas in Philadelphia County, Pennsylvania. In these matters, the plaintiffs allege that they sustained various injuries (including neurological disorders) as a result of their ingestion of Reglan. While a host of drug manufacturers and pharmacies are named as defendants in each of the suits, claims have also been asserted against so-called “Patient Education Monograph” (“PEM”) defendants, including us. It is generally alleged in all of the actions that certain PEM defendants provided Reglan patient drug information to pharmacies which, in turn, provided that drug information to the pharmacies' customers, the plaintiffs in these actions. Plaintiffs further allege that the PEM defendants' patient drug information did not provide adequate warning information about the use of Reglan. Other PEM defendants have also been named in these and other similar actions. In general, the lawsuits have been procedurally consolidated in Philadelphia as mass tort actions. To date, none of the actions against Truven specifically identifies Truven as the author of a PEM that was supplied to a plaintiff. Instead, plaintiffs in these cases allege only that they read an unnamed PEM and, in effect, that it must have been published by at least one of the PEM defendants named in the action.
	Along with other PEM defendants, Truven made one dispositive motion to dismiss all the actions. While that motion to dismiss has been denied, it was without prejudice, permitting Truven to renew at a later stage in the litigation.
	Pending the resolution of an appeal by the co-defendant generic drug company defendants, the resolution of which will not affect the continuation of the actions against us, there has been no active discovery involving Truven. At this time, we believe that we have meritorious defenses to the claims in each of these actions.
	On December 15, 2011, Midwest Health Initiative, a client of our research business, requested arbitration of a dispute relating to our performance under a client services agreement. The arbitration proceedings were initiated in St. Louis and were settled by both parties during the fourth quarter of 2013. The settlement was immaterial.
	Pacific Alliance Medical Center (“PAMC”) claimed in 2007 that we failed to properly submit some of PAMC’s data, resulting in denial of Medicare reimbursement to PAMC in the approximate amount of $600,000. PAMC was denied relief by administrative agencies and appealed to the U.S. District Court in the Central District of California for judicial review, which was denied. PAMC later appealed to the United States Court of Appeals for the Ninth Circuit and that appeal is currently pending. The parties have entered into a tolling agreement pending the outcome of PAMC’s appeal. If a claim is filed against us, we expect to defend it.
	The Company is involved in other litigation proceedings arising from the normal course of its operations. Related reserves are recorded when it is probable that liabilities exist and where reasonable estimates of such liabilities can be made.
	While it is not possible to predict the outcome of any of these proceedings, the Company's management, based on its assessment of the facts and circumstances now known, does not believe that any of these proceedings, individually or in the aggregate, will have a material adverse effect on the Company's financial position, results of operations and cash flows.

Segment_Information_Notes

Segment Information (Notes)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Information	'
	Segment Information
	The Company operates and manages its business through three reportable segments: Payer, Hospitals and Clinicians. The determination of reportable segments was based on the discrete financial information provided to the Chief Operating Decision Maker (“CODM”). The Chief Executive Officer has the authority for resource allocation and assessment of the Company’s performance and is, therefore, the CODM. The accounting policies for the reportable segments are the same as those for the combined Company. The Company’s operations and customers are based primarily in the United States. Each segment also offers distinct integrated products and services related to data analytics and solution platforms offered to customers or groups of similar customers. Results from operating activities represent the profit earned by each segment without allocation of central administrative revenues and expenses, financial income and expenses and income tax benefit and expense. The Company's segments are as follows:
	Payer
	The Payer segment provides information and solutions to various customer channels, such as employers and health plans, pharmaceutical companies, the federal government, and state governments, to improve the cost and quality of healthcare. These solutions focus on care and risk management, which enhance benefit design, medical cost trend management, disease management, network design and quality management processes in healthcare payer and purchasing organizations.
	Hospitals
	The Hospitals segment provides data, analytics, solutions and value‑added services to healthcare providers. These solutions benchmark customer data and evaluate customers’ performance against peer organizations. Typical benchmarks include costs, operational efficiencies, clinical performance and re-admissions.
	Clinicians
	The Clinicians segment delivers high value content, solutions and sophisticated decision support tools to nurses, physicians and pharmacists. These solutions and tools are aimed at improving patient care, reducing medication errors and enhancing disease and condition management.
	Segment information for the Successor Periods December 31, 2013, from inception (April 20, 2012) to December 31, 2012, and for the Predecessor Period January 1, 2012 to June 6, 2012, and for the Predecessor Period December 31, 2011 is as follows:
		Year ended December 31, 2013
		Successor
		Revenues			Depreciation			Segment
					and			Operating
					Amortization(1)			Income
								(Expense) (3)
	Payer	$	259,341		$	26,670		$	38,158
	Hospitals	123,692			15,301			16,646
	Clinicians	109,669			11,142			30,655
	Segment totals	492,702			53,113			85,459
	Center/Other(2)	—			—			(8,610		)
		$	492,702		$	53,113		$	76,849
		From inception (April 20, 2012) to December 31, 2012
		Successor
		Revenues			Depreciation			Segment
					and			Operating
					Amortization(1)			Income
								(Expense) (3)
	Payer	$	136,922		$	10,978		$	27,060
	Hospitals	59,300			6,352			4,353
	Clinicians	45,563			4,840			3,231
	Segment totals	241,785			22,170			34,644
	Center/Other(2)	1			—			-586
		$	241,786		$	22,170		$	34,058
		January 1 to June 6, 2012
		Predecessor
		Revenues			Depreciation			Segment
					and			Operating
					Amortization(1)			Income
								(Expense) (3)
	Payer	$	106,482		$	9,539		$	15,411
	Hospitals	53,236			5,520			8,222
	Clinicians	49,277			4,206			14,347
	Segment totals	208,995			19,265			37,980
	Center/Other(2)	3			—			(23,390		)
		$	208,998		$	19,265		$	14,590
		Year ended December 31, 2011
		Predecessor
		Revenues			Depreciation and Amortization(1)			Segment
								Operating
								Income
								(Expense) (3)
	Payer	$	245,065		$	23,795		$	37,378
	Hospitals	124,980			9,323			29,231
	Clinicians	111,672			5,941			33,746
	Segment totals	481,717			39,059			100,355
	Center/Other(2)	1,490			—			(35,993		)
		$	483,207		$	39,059		$	64,362
	(1)    Depreciation and amortization expense includes the depreciation of hardware and other tangible assets and the amortization of developed technology and content, but excludes the amortization of other identifiable intangible assets because the CODM during both the Predecessor and Successor Periods did not consider this item when allocating resources and assessing performance.
	(2)    Center/Other costs consist of items that are not directly attributable to reportable segments, revenue of discontinued product, marketing, technical support, executive, administrative costs and allocations from the Predecessor Parent. Center/Other includes the elimination of inter company transactions.
	(3)    Segment operating income (expense) excludes goodwill impairment charge because the CODM does not consider this item when allocating resources and assessing performance.
	The following table reconciles segment operating income per the reportable segment information to loss before income taxes per the consolidated and combined statements of comprehensive loss.
		Year ended December 31,				From inception (April 20, 2012) to December 31,					January 1, 2012 to June 6,			Year ended December 31,
		2013				2012					2012			2011
	Successor									Predecessor
Segment operating income	$	76,849			$	34,058				$	14,590		$	64,362
Amortization of other identifiable intangible assets	(34,460		)		(19,527		)			(8,226		)	(19,691		)
Goodwill impairment	(366,662		)		—					—			—
Other operating expenses	(35,038		)		(49,622		)			(18,803		)	(20,002		)
Operating income (loss)	(359,311		)		(35,091		)			(12,439		)	24,669
Interest expense to Predecessor Parent	—				—					—			134
Interest income	—				—					3			—
Interest expense	(70,581		)		(49,014		)			—			(63		)
Other finance costs	(24		)		—					—			—
Income (loss) before income taxes	$	(429,916	)		$	(84,105	)			$	(12,436	)	$	24,740
Reportable segment asset information is not disclosed because it is not reviewed by the CODM for purposes of evaluating performance and allocating resources.

Related_Party_Transactions_Not

Related Party Transactions (Notes)	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Related Party Transactions
	Predecessor
	Our Predecessor utilized various wholly-owned affiliates of Thomson Reuters to provide administrative services and to finance its operations. In accordance with SEC Staff Accounting Bulletin 1-B, “Allocation of Expenses and Related Disclosure in Financial Statements of Subsidiaries, Divisions or Lesser Business Components of Another Entity,” the condensed consolidated and combined financial statements include an allocation of the Predecessor Parent's corporate expenses to our Predecessor, which principally consisted of personnel costs, including salaries, employee benefits and share-based compensation expenses. These costs relate to the corporate executive offices, audit fees, legal services, treasury, communications, human resources, tax services, risk management, technology support, rent and other costs incurred by the Predecessor Parent and its subsidiaries on behalf of our Predecessor. Costs were allocated to the Company based primarily on the proportional revenue. The amounts allocated to the Company for the period ended June 6, 2012 are presented in the combined statement of comprehensive income (loss) as follows:
		January 1, 2012 to June 6, 2012		Year ended December 31, 2011
	Cost of revenues, excluding depreciation and amortization	$	4,868	$	10,213
	Allocation of costs from Predecessor Parent and affiliates	10,003		34,496
		$	14,871	$	44,709
	The allocations included within “Cost of revenues, excluding depreciation and amortization” comprised technology support administered by the Predecessor Parent related to customer data. Allocations were generally computed based on usage metrics.
	The Company believes the assumptions and methodologies underlying the allocations of general corporate overhead from Predecessor Parent were reasonable. However, such expenses may not be indicative of the actual expenses that would have been or will be incurred by TRHI or Truven operating as an independent company. As a result, the financial information herein may not necessarily reflect the combined financial position, results of operations and cash flows of the Company in the future or what it would have been if TRHI or Truven had been an independent company during the periods presented.
	If TRHI or Truven had operated independently of the Predecessor Parent, it is possible that the terms and conditions of these related party transactions, and the resulting amounts recorded, would have been different from those presented in these consolidated and combined financial statements.
	Immediately prior to the Acquisition, a related legal entity, Thomson Reuters Applications, Inc. ("TR Apps"), legally transferred certain fixed assets to TRHI for consideration of $15,975, which was settled via our net intercompany position.  Pursuant to the applicable tax law, while TRHI and TR Apps are part of the same consolidated tax return, no gain/loss or step-up in tax basis was recognized at the time of transfer.  At the close of the Acquisition on June 6, 2012, TRHI ceased to be part of the consolidated tax return group, which resulted in a step up in tax basis for the TR Apps assets.
	Successor
	The Company entered into an advisory agreement with the Sponsor, under which the Sponsor provided certain advisory services to the Company. As compensation for the services, the Company paid a transaction fee at the closing of the Acquisition and will continue to pay the Sponsor an annual advisory fee which will be equal to an aggregate amount equal to the greater of (i) $2.5 million and (ii) 2.0% of consolidated EBITDA (as defined in the credit agreement governing our Senior Credit Facility), as well as transaction fees on future acquisitions, divestitures, financings and liquidity events, which will be determined based upon aggregate equity investments at the time of such future events or on the value of the transaction. For the year ended December 31, 2013 and the period from April 20, 2012 to December 31, 2012, the Company recorded an expense of $2.9 million and $1.5 million, respectively, which represented the Sponsor advisory fee and is presented within other operating expenses in the Company's consolidated statements of comprehensive loss. As of December 31, 2013, the Company has a prepaid sponsor fee of $0.7 million included in the prepaid account and other current assets account in the balance sheet.
	After the Acquisition, the Company continued to receive certain administrative services (including facilities management, human resource management, finance and accounting operations, treasury, sourcing and procurement and IT services, among other services necessary for the conduct of the business) from Thomson Reuters under the terms of the Transitional Services Agreement. Such services are reflected as third-party activity in the Successor's financial statements. As of December 31, 2013, we have completed our administrative infrastructure, and most of these functions have been assumed by us or by third parties on our behalf including the hosting services of certain technology infrastructure. The expense incurred under this service agreement for the year ended December 31, 2013, and period from April 20, 2012 to December 31, 2012, totaled $10.5 million and $12.3 million, respectively, which is included in the other operating expenses in the consolidated statements of comprehensive loss.
	The Company also entered into a reverse transitional services agreement with TRUSI pursuant to which we provide TRUSI with office space and facilities management services at several locations in the United States. Pursuant to the agreement, we will provide these services for certain pre-determined periods ranging from one year to approximately 22 months, with all such services to end by March 31, 2014. The Company is entitled to fees for each of the services provided for any services requested by the Stock Seller. The income recognized under this service agreement for the year ended December 31, 2013 and period from April 20, 2012 to December 31, 2012, totaled $0.7 million and $0.5 million, respectively, which is recorded as a reduction to general and administrative expense in the Company's consolidated statement of comprehensive loss.
	During 2013, the Company received $2,350 of additional capital contribution from Holdings LLC, its direct parent company.

Fair_Value_Measurement_Notes

Fair Value Measurement (Notes)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurement	'
	Fair Value Measurement
	Fair value is defined under the Fair Value Measurements and Disclosures Topic of the Codification, FASB ASC 820, as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under FASB ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard established a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:
	• Level 1—Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.
	• Level 2—Inputs, other than quoted prices included within Level 1, which are observable for the asset or liability, either directly or indirectly. These are typically obtained from readily-available pricing sources for comparable instruments.
	• Level 3—Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own assumptions of the data that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.
	Under the Financial Instruments Topic of the Codification, ASC 825, entities are permitted to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value measurement option under ASC 825 for any of its financial assets or liabilities.
	For purposes of financial reporting, the Company has determined that the fair value of financial instruments including accounts receivable and accounts payable approximates carrying value at December 31, 2013 and December 31, 2012.
	At December 31, 2013, the carrying amounts and fair values of the Senior Credit Facility, Revolving Credit Facility and 10.625% Senior Notes were as follows:
				Fair values
		Carrying amounts		Level 1		Level 2		Level 3
	Senior Term Loan	$	516,831	$	—	$	531,625	$	—
	Revolver	30,000		—		30,000		—
	10.625% Senior Notes	325,427		—		369,876		—
	At December 31, 2012, the carrying amounts and fair values of the Senior Term Loan and 10.625% Senior Notes were as follows:
				Fair values
		Carrying amounts		Level 1		Level 2		Level 3
	Senior Term Loan	$	512,813	$	—	$	528,242	$	—
	10.625% Senior Notes	325,159		—		348,415		—
	Our level 2 inputs are determined based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the liabilities. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs including interest rate curves.
	As discussed in note 8, the company recorded an aggregate impairment charge of $366.7 million in the fourth quarter of 2013, to reflect the amount by which the carrying value of each reporting unit's goodwill exceeded the estimated fair value. The impairment charge did not impact the Company’s cash flows or liquidity. The fair value of goodwill was measured using Level 3 inputs such as discounted cash flows, market multiple analysis, replacement costs and sales comparison methodologies.

Subsequent_Events_Notes

Subsequent Events (Notes)	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	Subsequent Events
	In January 2014, management initiated a plan that will change the Company’s segment structure in mid 2014 with the objective of focusing on more effective business and market facing opportunities and to simplify the business decision-making process. The operating segments are expected to be realigned to Commercial and Government division structures that will be headed by a separate segment manager directly reporting to the Chief Operating Decision Maker ("CODM"). Management is currently evaluating the impact of these changes in the future financial statements.
	On February 14, 2014, the Company repaid $15 million of principal amount plus interest drawn against the Revolving Credit Facility.
	There have been no other events subsequent to December 31, 2013 which would require accrual or disclosure in these consolidated and combined financial statements.

Supplemental_Guarantor_Financi

Supplemental Guarantor Financial Information (Notes)	12 Months Ended
	Dec. 31, 2013
Condensed Financial Information of Parent Company Only Disclosure [Abstract]	'
Supplemental Guarantor Financial Information	'
	Supplemental Guarantor Financial Information
	In connection with the Acquisition, Truven issued the Notes as further described in Note 11. The Notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis by the Company and each of Truven’s existing and future wholly-owned domestic restricted subsidiaries (of which there currently are none) that is a borrower under or that guarantees the obligations under the Senior Credit Facility or any other indebtedness of Truven or any other guarantor. All obligations under the Senior Credit Facility are also guaranteed by the Company and each of Truven’s wholly-owned domestic subsidiaries (of which there are currently none). All obligations under the Senior Credit Facility and the guarantees of those obligations are secured by first priority security interests in substantially all of Truven’s assets, as well as those of each guarantor (subject to certain limited exceptions).
	The separate financial statements and the condensed consolidating and combining financial information about the results of operations, financial position and cash flows of the Parent, the Issuer, the Guarantors, the non-Guarantors, and eliminations are not presented due to the following:
	•	Truven (the Issuer) is 100% owned by the Company (the Parent guarantor)
	•	The guarantee is full and unconditional and there are no subsidiary guarantors
	•	The Company has no independent assets or operations.
	•	The transaction costs related to the Acquisition of $26,734 were incurred and paid for by Wolverine, which was merged with and into TRHI, with TRHI surviving the Merger upon closing of the Acquisition as a 100% owned direct subsidiary of the Company and TRHI subsequently changing its name to Truven Health Analytics Inc.
	•	The subsidiaries of the Company other than Truven, which were newly formed in the fourth quarter of 2012, are minor (as defined in Section 3-10(h)(6) of Regulation S-X of the Securities Act), having total assets, stockholders’ equity, revenues, operating income (before income taxes) and cash flows from operating activities of less than 3% of the Company’s corresponding consolidated amounts.

Supplemental_condensed_financi

Supplemental condensed financial information of the Parent Company	12 Months Ended
	Dec. 31, 2013
Condensed Financial Information of Parent Company Only Disclosure [Abstract]	'
Supplemental condensed financial information of the Parent Company	'
	Supplemental condensed financial information of the Parent Company
	Truven Holding Corp.
	SCHEDULE I—Condensed Financial Information of Parent Company
	Parent Company Condensed Balance Sheet
	(in thousands of dollars, unless otherwise indicated)
		As of December 31,
		2013			2012
	Asset
	Investments in Truven Health Analytics Inc.	$	79,283		$	419,252
	Total assets	79,283			419,252
	Liabilities and Equity
	Total liabilities	—			—
	Equity
	Common stock—$0.01 par value; 1,000 shares authorized, 1 share issued and outstanding at December 31, 2013 and 2012	—			—
	Additional paid in capital	478,549			473,364
	Accumulated deficit	(399,101		)	(54,112		)
	Currency translation adjustment	(165		)	—
	Total liabilities and stockholders’ equity	$	79,283		$	419,252
	The accompanying notes are an integral part of these condensed financial statements.
	Truven Holding Corp.
	Parent Company Condensed Statement of Comprehensive Loss
	(in thousands of dollars, unless otherwise indicated)
		For the year ended December 31, 2013			From inception (April 20, 2012) to December 31, 2012
	Revenues, net	$	—		$	—
	Operating costs and expenses	—			—
	(Loss) income before income taxes	—			—
	Benefit from (provision for) income taxes	—			—
	Income before share in net loss from subsidiaries	—			—
	Share of net loss from subsidiaries	(344,989		)	(54,112		)
	Net loss	$	(344,989	)	$	(54,112	)
	Other comprehensive loss:
	Foreign currency translation adjustments	$	(165	)	$	—
	Total comprehensive loss	$	(345,154	)	$	(54,112	)
	The accompanying notes are an integral part of these condensed financial statements.
	Truven Holding Corp.
	Parent Company Condensed Statement of Cash Flows
	(in thousands of dollars, unless otherwise indicated)
		For the year ended December 31, 2013			From inception (April 20, 2012) to December 31, 2012
	Net cash provided by operating activities	$	—		$	—
	Cash flows from investing activities:
	Investment in Truven Health Analytics, Inc.	(2,350		)	(464,400		)
	Net cash used in investing activities	(2,350		)	(464,400		)
	Cash flows from financing activities:
	Issuance of common stock	—			464,400
	Additional capital contribution	2,350			—
	Net cash provided by financing activities	2,350			464,400
	Change in cash and cash equivalents	—			—
	Cash and cash equivalents at the beginning of the period	—			—
	Cash and cash equivalents at the end of the period	$	—		$	—
	The accompanying notes are an integral part of these condensed financial statements.
	Truven Holding Corp.
	Notes to Parent Company Condensed Financial Statements
	(in thousands of dollars, unless otherwise indicated)
	Basis of Presentation
	The financial statements for Truven Holding Corp. (the “Parent Company”) summarize the results of operations and cash flows of the Parent Company for the year ended December 31, 2013 and from inception (April 20, 2012) to December 31, 2012 and its financial position as of December 31, 2013 and 2012.
	The separate condensed financial statements of the Parent Company as presented have been prepared in accordance with SEC Regulation S-X Rule 5-04 and Rule 12-04 and present the Parent Company’s investment in its subsidiaries under the equity method of accounting. Such investment is presented on a separate condensed balance sheet of the Parent Company as “Investment in Truven Health Analytics Inc.” and the Parent Company’s shares of profit or loss of subsidiaries are presented as “Share of net loss from subsidiaries” in the condensed statement of comprehensive loss.
	The Senior Credit Facility contains a number of covenants that, among other things, restrict, subject to certain exceptions, Truven’s ability and the ability of each of any restricted subsidiaries to sell assets, incur additional indebtedness, prepay other indebtedness (including the Notes), pay dividends and distributions or repurchase its capital stock, create liens on assets, make investments, make certain acquisitions, engage in mergers or consolidations, engage in certain transactions with affiliates, amend certain charter documents and material agreements governing subordinated indebtedness, change the business conducted by Truven and its subsidiaries, and enter into agreements that restrict dividends from subsidiaries. These restrictions have resulted in restricted net assets (as defined in Rule 4-08(e)(3) of Regulation S-X) of Truven and its subsidiaries totaling $79,283 and $419,252 as of December 31, 2013 and 2012, respectively, which exceeded 25% of the consolidated net assets of the Parent Company, and its subsidiaries.
	Capital Contribution
	The Parent Company was formed on April 20, 2012 for the purpose of consummating the Acquisition and has had no operations from inception. The Parent Company has 1,000 shares authorized, and issued 1 share with $0.01 par value for $464,400.
	Prior to the Acquisition, Thomson Reuters Corporation (the Predecessor Parent) entered into a Retention Agreement with key employees of TRHI in conjunction with the disposal of the business. Pursuant to the Retention Agreements, the Predecessor Parent provided for retention and bonus payment to certain employees based on a percentage of salary and targeted transaction price, respectively. The payment was contingent upon the employees continuing services to the buyer after the Acquisition for periods ranging from 90 days to one year. After the Acquisition, Truven determined that the retention and bonus for the duration of the performance period of certain employees subject to the Retention Agreement amounted to $15,813. Although the Predecessor Parent retained the legal and contractual obligation to pay the employees, the compensation expense was recorded by Truven in the period when the service was performed and was allocated in proportion to the days of service in both Predecessor and Successor Periods. As a result, for the Predecessor Period ended June 6, 2012, TRHI recorded $5,800 of retention and bonus expense against Net Investment of Predecessor Parent and Truven recorded $8,635 and $1,378 of retention and bonus expenses against Additional Paid in capital in the period from April 20, 2012 to December 31, 2012 and year ended December 31, 2013. The retention and bonus expense, which was paid by Predecessor Parent, was deemed an investment/capital contribution.
	During 2013, Truven Holding Corp. received $2,350 of additional capital contribution from VCPH Holdings LLC, its direct parent company.
	Contingencies
	As of December 31, 2013, there were no material contingencies, significant provisions for long-term debt obligations, or guarantees of the Parent Company, except for those, if any, which have been separately disclosed in the consolidated and combined financial statements.

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts (Notes)	12 Months Ended
	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]	'
Valuation and Qualifying Accounts	'
	Valuation and Qualifying Accounts
	We maintain an allowance for doubtful accounts that is recorded as a contra asset to our accounts receivable balance. The following table sets forth the change in this reserve for the years ended December 31, 2013 (Successor), form inception (April 20, 2012) to December 1, 2012 (Successor), for the period January 1, 2012 to June 6, 2012 (Predecessor), and year ended December 31, 2011 (Predecessor).
	Valuation and Qualifying Accounts
	Allowance for Doubtful Accounts		Balance at Beginning of Year	Charge to (Recovery from) Bad Debt (1)		Write-offs Net of Recoveries (2)		Balance at End of Year
	Year ended December 31, 2013 (Successor)		1,865.00	(144.0	)	191		1,530
	From inception (April 20, 2012) to December 31, 2012 (Successor)		—	517		(1,348.0	)	1,865.00
	For the period January 1, 2012 to June 6, 2012 (Predecessor)		1,319.00	—		1,319.00		—
	Year ended December 31, 2011 (Predecessor)		850	466		(3.0	)	1,319
		-1	Additions to the allowance account through the normal course of business are charged to expense.
		-2	Write-offs reduce the balance of accounts receivable and the related allowance for doubtful accounts indicating management’s belief that specific balances are not recoverable.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The consolidated and combined financial statements of Successor and combined financial statements of our Predecessor have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). All significant intercompany balances and transactions have been eliminated in the consolidated and combined financial statements.
	Successor-The consolidated financial statements as of December 31, 2013, and for the periods from April 20, 2012 through December 31, 2012 and from January 1, 2013 through December 31, 2013 include the accounts of the Company from inception and its subsidiaries subsequent to the closing of the Acquisition on June 6, 2012. The consolidated financial statements of the Successor reflect the Acquisition under the acquisition method of accounting, in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combinations.
	Predecessor-The accompanying combined financial statements of the Thomson Reuters Healthcare business (our “Predecessor”) prior to the Acquisition, include the combined financial statements of TRHI and certain assets owned by subsidiaries of Thomson Reuters Corporation (“Thomson Reuters” or the “Predecessor Parent”).
	Before the Acquisition, our Predecessor operated as a business unit of Thomson Reuters and not as a standalone company. TRHI was a wholly-owned indirect subsidiary of Thomson Reuters, and certain of the company's assets were owned by subsidiaries of Thomson Reuters. During the Predecessor Period, TRHI engaged in extensive intercompany transactions with Thomson Reuters and its subsidiaries related to certain support services, and Thomson Reuters allocated the cost of these services as “Allocation of costs from Predecessor Parent and affiliates” in the combined statement of comprehensive income (loss) (see Note 18). For the Predecessor Period, the accompanying combined financial statements reflect the assets, liabilities, revenues and expenses directly attributed to the Thomson Reuters Healthcare business as well as certain allocations by the Predecessor Parent. All significant transactions in the Predecessor Period between TRHI and other Thomson Reuters entities were included in our Predecessor's combined financial statements. The expense and cost allocations were determined on bases that were deemed reasonable by management in order to reflect the utilization of services provided or the benefit received by TRHI during the periods presented. The combined financial information included herein does not necessarily reflect the results of operations, financial position, changes in equity and cash flows of the Company in the future or what would have been reflected had we operated as a separate, standalone entity during the periods presented. The income tax benefits and provisions, related tax payments and deferred tax balances were prepared as if the Predecessor had operated as a standalone taxpayer for the Predecessor Periods presented.
	From January 1, 2009 to June 30, 2011, our Predecessor was reported on a combined basis with Thomson Reuters’ former Scientific segment to form the Healthcare and Science segment of the Predecessor Parent. Effective June 30, 2011, our Predecessor was reported separately following the Predecessor Parent’s announcement of its intention to dispose of the Thomson Reuters Healthcare business. Reflecting the manner in which the business was managed in each period, certain shared costs of the combined Healthcare and Science segment incurred prior to June 30, 2011, were allocated to our Predecessor and are reported within “Allocation of costs from Predecessor Parent and affiliates.” Subsequent to June 30, 2011, these costs are included within “General and administrative, excluding depreciation and amortization” in the combined statement of comprehensive income (loss).
	“Notes receivable from Predecessor Parent” is separately identified on the combined balance sheet, as it relates to a specific agreement between TRHI and the Predecessor Parent. All other intercompany activity with the Predecessor Parent or affiliates, which was not subject to written loan agreements, was included in “Net investment of Predecessor Parent” in the combined balance sheet. All transactions recorded through the “Net investment of Predecessor Parent,” with the exception of the noncash dividend discussed in Note 18, are reflected as financing activities in the accompanying combined statements of cash flows.
	The Company is a wholly-owned subsidiary of VCPH Holdings LLC (“Holdings LLC”) and has no operations other than its investment in Truven. Therefore, the condensed consolidated and combined financial statements of the Company reflect the financial position and results of operations of Truven.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates are based on management’s knowledge of current events and actions that the Company may undertake in the future, actual results could differ from those estimates. These estimates include, but are not limited to, allowance for doubtful accounts, realization of deferred tax assets, the determination of fair values used in the assessment of the realizability of long lived assets, goodwill and identifiable intangible assets, purchase accounting and the allocation of certain expenses to TRHI by TRUSI with respect to the Predecessor combined financial statements.
Acquisitions	'
	Acquisitions
	Acquisitions are accounted for using the acquisition method in accordance with the Financial Accounting Standards Board (“FASB”) ASC Topic 805, Business Combinations, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition. The excess of the cost of an acquired entity over the amounts assigned to assets acquired and liabilities assumed in a business combination is recognized as goodwill. The results of acquired businesses are included in the consolidated and combined financial statements from the dates of acquisition.
	Transaction costs that the Company incurs in connection with an acquisition are expensed as incurred. During the measurement period the Company reports provisional information for a business combination if by the end of the reporting period in which the combination occurs the accounting is incomplete. The measurement period, however, ends at the earlier of when the acquirer has received all of the necessary information to determine the fair values or one year from the date of the acquisition. The finalization of the valuations may result in the refinement of assumptions that impact not only the recognized value of such assets, but also amortization and depreciation expense. In accordance with ASC 805 and the Company’s policy, any adjustments on finalization of the preliminary purchase accounting are recognized retrospectively from the date of acquisition.
Revenue recognition	'
	Revenue recognition
	The Company recognizes revenue when all of the following four criteria are met:
	•persuasive evidence of an arrangement exists;
	•delivery has occurred or services have been rendered;
	•the fee is fixed or determinable; and
	•collectability is reasonably assured.
	Subscription based products
	Subscription revenues from sales of products and services that are delivered under a contract over a period of time are recognized on a straight line basis over the term of the subscription. Where applicable, usage fees above a base period fee are recognized as services are delivered. Subscription revenue received or receivable in advance of the delivery of services or publications is included in deferred revenue.
	Multiple element arrangements
	The Company’s hosting arrangements are typically comprised of two deliverables: (1) the design, production, testing and installation of the customer’s database; and (2) the provision of ongoing data management and support services in conjunction with licensed data and software. Such deliverables are accounted for as separate units of accounting if the following criteria are met:
		For contracts entered into prior to January 1, 2011, revenue is allocated to a deliverable if vendor specific objective evidence (“VSOE”) or third party evidence (“TPE”) for that deliverable is available. The amount allocated to each deliverable is then recognized as revenue when delivery has occurred or services have been rendered with respect to that deliverable, provided that all other relevant revenue recognition criteria are met. VSOE generally exists only when the Company sells the deliverables separately and is the price actually charged by the Company for that deliverable. For contracts entered into prior to January 1, 2011, the Company is not able to establish VSOE or TPE for the deliverables in its hosting arrangements. As a result, such deliverables are treated as one unit of accounting, and the revenue is recognized over the ongoing service period.
		For contracts entered into or materially modified on or after January 1, 2011, revenue is allocated to deliverables based upon the following hierarchy: (i) VSOE; (ii) TPE; and (iii) best estimate of selling price (“ESP”). The objective of ESP is to determine the price at which the Company would offer each unit of accounting to customers if each unit were sold regularly on a standalone basis. The Company uses a cost plus a reasonable margin approach to determine ESP for each deliverable. Revenue related to database production is recognized using a proportional performance model, with reference to labor hours. Revenue related to ongoing services is recognized on a straight line basis over the applicable service period, provided that all other relevant criteria are met. For contracts entered into on or after January 1, 2011, the Company was able to separate the production of the database installation deliverable and the ongoing services deliverable into two separate units of accounting given that the deliverables have value to the customer on a standalone basis. The revenue is allocated to these units of accounting based upon relative ESP.
	Software-related products and services
	Certain arrangements include implementation services as well as term licenses to software and other software related elements, such as post contract customer support. Revenues from implementation services associated with installed software arrangements are accounted for separately from software and subscription revenues using the proportional performance model, with reference to labor hours, if VSOE is available for the elements of the arrangement. If the implementation services do not qualify for separate accounting, they are recognized together with the related software and subscription revenues on a straight line basis over the term of service.
Advertising costs	'
	Advertising costs
	Costs incurred for producing and communicating advertising are expensed when incurred.
Research and development costs	'
	Research and development costs
	Research and development (“R&D”) costs are expensed as incurred.
Cash and cash equivalents	'
	Cash and cash equivalents
	Cash and cash equivalents are comprised of cash on deposit in banks. Cash equivalents have original maturities of less than 90 days. During the Predecessor Period, TRHI and the Predecessor Parent had an agreement whereby the Predecessor Parent periodically swept TRHI’s cash receipts and funded TRHI’s cash disbursements. With the exception of activity associated with “Notes receivable from Predecessor Parent,” described below, such activity is included in “Net investment of Predecessor Parent” on the combined balance sheet.
Trade receivables	'
	Trade receivables are classified as current assets and are reported net of an allowance for doubtful accounts. The Company assesses the allowance for doubtful accounts periodically, evaluating general factors such as the length of time individual receivables are past due, historical collection experience, and the economic and competitive environment. Management believes that the allowances at December 31, 2013 and 2012 are adequate to cover potential credit loss.
Computer hardware and other property	'
	Computer hardware and other property
	Computer Hardware and Other Property are stated at cost less accumulated depreciation. Depreciation is computed on a straight line basis over the following estimated useful lives:
	Computer hardware	3-5 years
	Furniture, fixtures and equipment	5-7 years
	Leasehold improvements	Lesser of lease term  or
		estimated useful life
Developed technology and content	'
	Developed technology and content
	Certain costs incurred in connection with software to be used internally are capitalized once a project has progressed beyond a conceptual, preliminary stage to that of application development stage. Costs that qualify for capitalization include both internal and external costs, but are limited to those that are directly related to a specific project. The capitalized amounts, net of accumulated amortization, are included in “Developed technology and content, net” on the balance sheets.
	Developed technology and content is stated at cost less accumulated amortization. Amortization is computed based on the expected useful life of three to ten years.
Goodwill and other identifiable intangible assets	'
	Goodwill and other identifiable intangible assets
	Goodwill is tested for impairment annually on November 1 of each year, or more frequently if indications of potential impairment exist. The Company performs a qualitative assessment (Step zero analysis) by identifying relevant events and circumstances such as industry specific trends, performance against forecasts and other indicators on a reporting unit level to determine whether it is necessary to perform the two step goodwill impairment test. For purposes of the goodwill impairment test, the reporting units of the Company, after considering the requirements of ASC 350, and the relevant provisions of the Segment Reporting Topic of the Codification, ASC 280, and related interpretive literature, represents the three reportable segments: Payer; Hospitals; and Clinicians. Under the two step approach, the first step is to determine the fair value of the reporting unit. Fair value is determined considering the income approach (discounted cash flow) and market approach. If the fair value of a reporting unit is less than its carrying value, this is an indicator that the goodwill assigned to that reporting unit may be impaired. In this case, the second step is to allocate the fair value of the reporting unit to the assets and liabilities of the reporting unit, as if they had just been acquired in a business combination for the fair value of the reporting unit. The excess of the fair value of the reporting unit over the amounts allocated to its assets and liabilities is referred to as the implied fair value of goodwill. The implied fair value of the reporting unit’s goodwill is then compared to the actual carrying value of goodwill. If the implied fair value is less than the carrying value, an impairment loss is recognized for that excess.
	Identifiable intangible assets with finite lives are amortized over their estimated useful lives. The carrying values of identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. The estimated useful lives for these identifiable intangible assets are as follows:
	Trade names	15 years
	Customer relationships	11-12 years
Impairment of long lived assets	'
	Impairment of long lived assets
	Management evaluates the impairment of long-lived assets whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. The initial test for impairment compares the carrying amounts with the sum of undiscounted cash flows related to the asset. If the carrying value is greater than the undiscounted cash flows of the asset, the asset is written down to its estimated fair value.
Deferred Financing Costs	'
	Deferred Financing Costs
	Deferred financing costs are incurred to obtain long-term financing and are amortized over the terms of the related debt.
Debt and Original Issue Discounts	'
	Debt and Original Issue Discounts
	On initial recognition, debts are measured at face value less original issue discount. Subsequent to initial recognition, interest bearing debts are measured at amortized cost. Original issue discount is amortized based on an effective interest rate method over the term of the debt. Original issue discount is presented net of debt in the Company’s consolidated balance sheet.
Fair Value Measurement	'
	Fair Value Measurement
	Fair value is defined under the Fair Value Measurements and Disclosures Topic of the Codification, ASC 820, as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard established a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:
	Level 1-Quoted prices in active markets for identical assets or liabilities. These are typically obtained from real-time quotes for transactions in active exchange markets involving identical assets.
	Level 2-Inputs, other than quoted prices included within Level 1, which are observable for the asset or liability, either directly or indirectly. These are typically obtained from readily-available pricing sources for comparable instruments.
	Level 3-Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting entity’s own assumptions of the data that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.
	Under the Financial Instruments Topic of the Codification, ASC 825, entities are permitted to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value measurement option under ASC 825 for any of its financial assets or liabilities.
Share-based compensation plans	'
	Share-based compensation plans
	The Predecessor Parent administered all share-based compensation plans on behalf of TRHI and applied the fair value recognition provisions of ASC 718, Compensation-Stock Compensation (“ASC 718”), to calculate the effect of such compensation on our Predecessor’s comprehensive loss in the Predecessor Period.
	Following the Acquisition, the Company’s immediate parent, Holdings LLC, established a compensation award in accordance with the Amended and Restated Limited Liability Company Operating Agreement of Holdings LLC (the “Operating Agreement”) to provide Class B Membership Interests in Holdings LLC to certain executive officers of the Company. The equity awards are accounted for by applying the fair value recognition provisions of ASC 718, to calculate the effect of such compensation on the Company’s net income in the Successor Periods.
Income taxes	'
	Income taxes
	The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”).
	For the Predecessor Period, income taxes are presented as if the Company operated as a separate standalone taxpaying entity (separate return basis). Income taxes payable by subsidiaries that file separate returns are included in “Income taxes payable” on the combined balance sheet. The Predecessor Parent files individual and combined tax returns that include TRHI as required within each jurisdiction.
	In the consolidated Successor financial statements, the Company utilizes the asset and liability method of accounting for income taxes, which requires that deferred tax assets and liabilities be recorded to reflect the future tax consequences of temporary differences between the book and tax basis of various assets and liabilities. A valuation allowance is established to offset any deferred tax assets if, based upon the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
	ASC 740 also provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements. ASC 740 requires evaluation of tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax position is “more likely than not” to be sustained by the applicable tax authority. Interest and penalties arising from an uncertain income tax position is included in our provision for income taxes. The Company did not have any material uncertain tax positions.
Recent accounting pronouncements	'
	Recent accounting pronouncements
	In February 2013, the FASB issued Accounting Standards Update No. 2013-02, Comprehensive Income (Topic 220) ("ASU 2013-02"). The amendments in ASU 2013-02 supersede and replace the presentation requirements for reclassifications out of accumulated other comprehensive income in ASU 2011-05 and ASU 2011-12 for all public and private organizations. The amendments would require an entity to provide additional information about reclassifications out of accumulated other comprehensive income. The amendments in ASU 2013-02 are effective prospectively for fiscal years, and periods within those years, beginning after December 15, 2012. The Company adopted ASU 2013-02 effective January 1, 2013. The adoption of this standard had no impact on the Company’s financial statements.
	In July 2013, the FASB issued ASU 2013-11, Income taxes (Topic 740):Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The amendment requires an unrecognized tax benefit or portion of an unrecognized tax benefit to be presented as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward except when certain conditions exist. The amendment in ASU 2013-11 is effective for the Company for fiscal years beginning after December 15, 2013, including periods in 2014. The adoption of this standard will not impact the Company's financial position, comprehensive loss or cash flows.
Segment Information	'
	Segment Information
	The Company operates and manages its business through three reportable segments: Payer, Hospitals and Clinicians. The determination of reportable segments was based on the discrete financial information provided to the Chief Operating Decision Maker (“CODM”). The Chief Executive Officer has the authority for resource allocation and assessment of the Company’s performance and is, therefore, the CODM. The accounting policies for the reportable segments are the same as those for the combined Company. The Company’s operations and customers are based primarily in the United States. Each segment also offers distinct integrated products and services related to data analytics and solution platforms offered to customers or groups of similar customers. Results from operating activities represent the profit earned by each segment without allocation of central administrative revenues and expenses, financial income and expenses and income tax benefit and expense. The Company's segments are as follows:
	Payer
	The Payer segment provides information and solutions to various customer channels, such as employers and health plans, pharmaceutical companies, the federal government, and state governments, to improve the cost and quality of healthcare. These solutions focus on care and risk management, which enhance benefit design, medical cost trend management, disease management, network design and quality management processes in healthcare payer and purchasing organizations.
	Hospitals
	The Hospitals segment provides data, analytics, solutions and value‑added services to healthcare providers. These solutions benchmark customer data and evaluate customers’ performance against peer organizations. Typical benchmarks include costs, operational efficiencies, clinical performance and re-admissions.
	Clinicians
	The Clinicians segment delivers high value content, solutions and sophisticated decision support tools to nurses, physicians and pharmacists. These solutions and tools are aimed at improving patient care, reducing medication errors and enhancing disease and condition management.

Description_of_Business_and_Ba1

Description of Business and Basis of Presentation Description of Business and Basis of Presentation (Tables)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Schedule of Prior Period Adjustments	'
	The following table summarizes the effects of the revision on the Company's segment reporting:
	Segment information from inception (April 20, 2012) to December 31, 2012 (Successor):
		As Reported			Adjustments				As Revised
		Depreciation and amortization	Segment operating income		Depreciation and amortization		Segment operating income		Depreciation and amortization	Segment operating income
	Payer	10,276	27,762		702		(702	)	10,978	27,060
	Hospitals	6,983	3,722		(631	)	631		6,352	4,353
	Clinicians	3,578	4,493		1,262		(1,262	)	4,840	3,231
	Segment total	20,837	35,977		1,333		(1,333	)	22,170	34,644
	Center	1,333	(1,919	)	(1,333	)	1,333		—	(586	)
	Total	22,170	34,058		—		—		22,170	34,058
	Segment information from period January 1, 2012 to June 6, 2012 (Predecessor):
		As Reported			Adjustments				As Revised
		Depreciation and amortization	Segment operating income		Depreciation and amortization		Segment operating income		Depreciation and amortization	Segment operating income
	Payer	8,249	16,701		1,290		(1,290	)	9,539	15,411
	Hospitals	6,516	7,226		(996	)	996		5,520	8,222
	Clinicians	3,480	15,073		726		(726	)	4,206	14,347
	Segment total	18,245	39,000		1,020		(1,020	)	19,265	37,980
	Center	1,020	(24,410	)	(1,020	)	1,020		—	(23,390	)
	Total	19,265	14,590		—		—		19,265	14,590
	Segment information for the period December 31, 2011 (Predecessor):
		As Reported			Adjustments				As Revised
		Depreciation and amortization	Segment operating income		Depreciation and amortization		Segment operating income		Depreciation and amortization	Segment operating income
	Payer	22,430	38,743		1,365		(1,365	)	23,795	37,378
	Hospitals	8,535	30,019		788		(788	)	9,323	29,231
	Clinicians	5,354	34,333		587		(587	)	5,941	33,746
	Segment total	36,319	103,095		2,740		(2,740	)	39,059	100,355
	Center	2,740	(38,733	)	(2,740	)	2,740		—	(35,993	)
	Total	39,059	64,362		—		—		39,059	64,362

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of computer hardware and other property useful lives	'
	Computer Hardware and Other Property are stated at cost less accumulated depreciation. Depreciation is computed on a straight line basis over the following estimated useful lives:
	Computer hardware	3-5 years
	Furniture, fixtures and equipment	5-7 years
	Leasehold improvements	Lesser of lease term  or
		estimated useful life
	Computer hardware and other property, net, consisted of the following:
		December 31, 2013
		Computer hardware			Building and leasehold improvements			Furniture, fixtures and equipment			Total
	Computer hardware and other property, gross	$	67,285		$	5,166		$	2,861		$	75,312
	Accumulated depreciation	(24,762		)	(1,124		)	(1,389		)	(27,275		)
	Computer hardware and other property, net	$	42,523		$	4,042		$	1,472		$	48,037
		December 31, 2012
		Computer hardware			Building and leasehold improvements			Furniture, fixtures and equipment			Total
	Computer hardware and other property, gross	$	40,494		$	3,106		$	3,425		$	47,025
	Accumulated depreciation	(5,929		)	(393		)	(512		)	(6,834		)
	Computer hardware and other property, net	$	34,565		$	2,713		$	2,913		$	40,191
Schedule of intangible asset useful lives	'
	The estimated useful lives for these identifiable intangible assets are as follows:
	Trade names	15 years
	Customer relationships	11-12 years

Acquisition_Tables

Acquisition (Tables)	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Allocation of the Purchase Price	'
	The following is a summary of the final allocation of the final purchase price of the Acquisition to the estimated fair values of assets acquired and liabilities assumed in the Acquisition. The final allocation of the purchase price is based on management's judgment after evaluating several factors, including a valuation assessment prepared by a third party valuation firm:
		Final values recognized at acquisition date
	Trade and other receivables	$	77,598
	Prepaid assets and other current assets	11,973
	Computer hardware and other property	24,693
	Developed technology and content	159,622
	Other identifiable intangible assets	416,000
	Other noncurrent assets	106
	Current deferred tax assets	11,262
	Current liabilities	(46,588		)
	Deferred revenue	(80,239		)
	Noncurrent deferred tax liabilities	(149,364		)
	Net assets acquired	425,063
	Goodwill on acquisition	824,339
	Net consideration paid in cash	$	1,249,402
Unaudited Pro Forma Financial Data	'
	The following unaudited pro forma financial data summarizes the Company’s results of operations for the years ended December 31, 2012 and 2011 had the Acquisition occurred as of the beginning of the comparable prior year:
			Years ended December 31,
			2012			2011
	Revenues, net		$	490,625		$	435,918
	Net loss		(11,173		)	(52,462		)

Trade_and_other_receivables_Ta

Trade and other receivables (Tables)	12 Months Ended
	Dec. 31, 2013
Receivables [Abstract]	'
Schedule of trade and other receivables	'
	Trade and other receivables consisted of the following:
		December 31, 2013			December 31, 2012
	Trade receivables, gross	$	99,011		$	106,699
	Less: Allowance for doubtful accounts	(1,530		)	(1,865		)
	Trade receivables, net	97,481			104,834
	Other receivables	317			307
	Trade and other receivables, net	$	97,798		$	105,141

Prepaid_and_other_current_asse1

Prepaid and other current assets (Tables)	12 Months Ended
	Dec. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Schedule of prepaid and other current assets	'
	Prepaid expenses and other current assets consisted of the following:
		December 31, 2013		December 31, 2012
	Royalties	$	3,502	$	3,559
	Commissions and distribution fees	9,046		5,618
	Services, licenses and maintenance	10,720		8,388
	Others	940		844
	Prepaid expenses and other current assets	$	24,208	$	18,409

Computer_hardware_and_other_pr1

Computer hardware and other property (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Schedule of computer hardware and other property	'
	Computer Hardware and Other Property are stated at cost less accumulated depreciation. Depreciation is computed on a straight line basis over the following estimated useful lives:
	Computer hardware	3-5 years
	Furniture, fixtures and equipment	5-7 years
	Leasehold improvements	Lesser of lease term  or
		estimated useful life
	Computer hardware and other property, net, consisted of the following:
		December 31, 2013
		Computer hardware			Building and leasehold improvements			Furniture, fixtures and equipment			Total
	Computer hardware and other property, gross	$	67,285		$	5,166		$	2,861		$	75,312
	Accumulated depreciation	(24,762		)	(1,124		)	(1,389		)	(27,275		)
	Computer hardware and other property, net	$	42,523		$	4,042		$	1,472		$	48,037
		December 31, 2012
		Computer hardware			Building and leasehold improvements			Furniture, fixtures and equipment			Total
	Computer hardware and other property, gross	$	40,494		$	3,106		$	3,425		$	47,025
	Accumulated depreciation	(5,929		)	(393		)	(512		)	(6,834		)
	Computer hardware and other property, net	$	34,565		$	2,713		$	2,913		$	40,191

Developed_technology_and_conte1

Developed technology and content (Tables)	12 Months Ended
	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'
Schedule of developed technology and content, net	'
	Other identifiable intangible assets, net, consisted of the following:
		December 31, 2013
		Average life (years)		Cost				Accumulated amortization			Net
	Customer relationships	11.5		$	329,800			$	(44,983	)	$	284,817
	Trademarks and trade names	15		86,200				(9,003		)	77,197
				$	416,000			$	(53,986	)	$	362,014
		December 31, 2012
		Average life (years)		Cost				Accumulated amortization			Net
	Customer relationships	11.5		$	329,800			$	(16,270	)	$	313,530
	Trademarks and trade names	15		86,200				(3,257		)	82,943
				$	416,000			$	(19,527	)	$	396,473
Developed technology and content	'
Finite-Lived Intangible Assets [Line Items]	'
Schedule of developed technology and content, net	'
	Developed technology and content, net, consisted of the following:
		31-Dec-13				31-Dec-12
	Developed technology and content, gross	$	195,961			$	175,828
	Accumulated amortization	(47,324		)		(15,493		)
	Developed technology and content, net	$	148,637			$	160,335

Goodwill_Tables

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of goodwill	'
	Balances and changes in the carrying amount of goodwill for the year December 31, 2013 and the Successor Period ended December 31, 2012 were as follows:
		Payer			Hospitals			Clinicians			Total
	Balance as of April 20, 2012	$	—		$	—		$	—		$	—
	Acquisition (see Note 3)	414,992			206,312			203,035			824,339
	Balance as of December 31, 2012	414,992			206,312			203,035			824,339
	Impairment charge	(207,918		)	(65,792		)	(92,952		)	(366,662		)
	Balance as of December 31, 2013	$	207,074		$	140,520		$	110,083		$	457,677

Other_identifiable_intangible_1

Other identifiable intangible assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of other identifiable intangible assets, net	'
	Other identifiable intangible assets, net, consisted of the following:
		December 31, 2013
		Average life (years)	Cost		Accumulated amortization			Net
	Customer relationships	11.5	$	329,800	$	(44,983	)	$	284,817
	Trademarks and trade names	15	86,200		(9,003		)	77,197
			$	416,000	$	(53,986	)	$	362,014
		December 31, 2012
		Average life (years)	Cost		Accumulated amortization			Net
	Customer relationships	11.5	$	329,800	$	(16,270	)	$	313,530
	Trademarks and trade names	15	86,200		(3,257		)	82,943
			$	416,000	$	(19,527	)	$	396,473

Accounts_payable_and_accrued_e1

Accounts payable and accrued expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Schedule of accounts payable and accrued expenses	'
	Accounts payable and accrued expenses
	Accounts payable and accrued expenses consisted of the following:
		December 31, 2013		December 31, 2012
	Accounts payable - trade	$	26,259	$	48,691
	Accrued employee compensation	13,529		23,953
	Accrued royalties	3,773		3,793
	Accrued professional fees	4,409		8,658
	Accrued interest	2,966		3,367
	Customer deposits	618		806
	Other accrued expenses	1,822		3,239
	Accounts payable and accrued expenses	$	53,376	$	92,507

Longterm_Debt_Tables

Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Schedule of Long-term Debt Instruments	'
	The Company's long-term debt consists of the following:
		December 31, 2013		December 31, 2012
	Senior Credit Facility
	Term Loan Facility (net of $14,156 and $12,174 discount, respectively)	$	516,831	$	512,813
	Revolving Credit Facility	30,000		—
	10.625% Senior Notes ("the Notes") (net of $1,723 and $1,991 discount, respectively)	325,427		325,159
		872,258		837,972
	Less: current portion of long-term debt	5,350		5,276
	Long-term debt	$	866,908	$	832,696
Schedule of Principal Maturities of Long-term Debt	'
	As of December 31, 2013, principal maturities of long-term debt for the next five years and thereafter consist of:
	2014	$	5,350
	2015	5,350
	2016	5,350
	2017	35,350
	2018	5,350
	Thereafter	810,158
		$	866,908

Sharebased_Compensation_Tables

Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Valuation Methods Used	'
	The following table summarizes the valuation methods used to measure fair value for each type of award and the related vesting period over which compensation expense is recognized:
	Type of award	Vesting period	Fair value measure	Compensation
				expense based on
	Stock options	Up to four years	Black-Scholes option pricing model	Fair value on business day prior to grant date
	TRSUs	Up to seven years	Closing Common share price	Fair value on business day prior to grant date
	PRSUs	Three year performance period	Closing Common share price	Fair value on business day prior to grant date
Valuation assumptions used	'
	The weighted average fair value of options granted and principal assumptions used in applying the Black-Scholes option pricing model were as follows:
		Predecessor
		January 1, 2012 to June 6, 2012	2011
	Weighted average grant date fair value	5.21	8.42
	Weighted average of key assumptions
	Exercise price	28.42	38.98
	Risk-free interest rate	1.20%	2.70%
	Dividend yield	3.40%	3.30%
	Volatility factor	28%	29%
	Expected life (in years)	6	6
Schedule of stock transactions	'
	Transactions related to the Predecessor Parent’s stock options in the Predecessor Period ended June 6, 2012 and the year ended December 31, 2011 are summarized as follows:
		Shares		Weighted			Weighted		Aggregate
				average			average		intrinsic value
				exercise			remaining		(in thousands)
				price			term
							(in years)
	Outstanding at December 31, 2011	270,753		$	34.16		7.38		$	182
	Granted	90,520		28.42			—		—
	Outstanding and exercisable at June 6, 2012	361,273		$	32.71		0		$	280
Schedule of restricted stock activity	'
	Transactions related to TRSUs and PRSUs in 2012 and 2011 are summarized as follows:
		TRSU				PRSU
		Shares		Weighted		Shares		Weighted
				average				average
				grant-date				grant-date
				fair value				fair value
	Outstanding at December 31, 2011	28,748		36.75		148,949		31.77
	Dividends accrued	110		—		1,138		—
	Granted	—		—		67,740		28.42
	Vested	(24,829	)	36.48		(41,016	)	23.46
	Vested (accelerated)	(4,029	)	38.55		(63,834	)	35.37
	Forfeited or expired	—		—		(112,977	)	31.13
	Outstanding at June 6, 2012	—		—		—		—
Transaction related to class B membership Interest	'
	Class B Membership Interests is as follows:
		Ownership interest (%)		Fair value at grant date
	Balance at December 31, 2012	4.1		$	5,714
	Granted	0.9		1,162
	Forfeited	(0.4	)	(502		)
	Balance at December 31, 2013	4.6		$	6,374
	Outstanding and vested as of December 31, 2013	0.8		$	1,143

Other_Operating_Expenses_Table

Other Operating Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Other Income and Expenses [Abstract]	'
Components of other operating expenses	'
	The components of other operating expenses include the following:
		Year ended December 31,		From inception (April 20, 2012) to December 31,		January 1, 2012 to June 6,		Year ended December 31,
		2013		2012		2012		2011
		Successor				Predecessor
	Disposal related costs	$	—	$	—	$	9,818	$	12,560
	Severance and retention bonuses	3,808		10,184		7,741		6,768
	Acquisition related costs	27,007		37,980		—		460
	Asset write-offs (see Note 16)	1,294		—		—		—
	Other	2,929		1,458		1,244		214
	Total other operating expenses	$	35,038	$	49,622	$	18,803	$	20,002

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Components of Income Tax Expense (Benefit)	'
	The components of income tax expense are as follows:
		Successor								Predecessor
		Year ended			From inception (April 20, 2012) to December 31, 2012					January 1, 2012 to June 6,			Year ended
		December 31,								2012			December 31,
		2013											2011
	Current
	Federal	$	—		$	—				$	(4,807	)	$	3,174
	State	235			82					(539		)	801
	Foreign	236			—					—			—
		471			82					(5,346		)	3,975
	Deferred
	Federal	(75,817		)	(26,189		)			477			5,353
	State	(9,472		)	(3,886		)			66			531
	Foreign	(109		)	—					—			—
		(85,398		)	(30,075		)			543			5,884
	Total (benefit from) provision for income taxes	$	(84,927	)	$	(29,993	)			$	(4,803	)	$	9,859
Schedule of Deferred Tax Assets and Liabilities	'
	The components of the net deferred tax liabilities as reported on the consolidated balance sheets are as follows:
		December 31,				December 31,
		2013				2012
	Current deferred tax asset	$	—			$	10,648
	Current deferred tax liabilities	(711		)		—
	Noncurrent deferred tax liabilities	(22,027		)		(118,675		)
	Net deferred tax asset (liabilities)	$	(22,738	)		$	(108,027	)
	The tax effects of the significant components of temporary differences giving rise to the Company’s deferred income tax assets and liabilities are as follows:
		December 31,					December 31,
		2013					2012
	Allowance for doubtful accounts and other reserves	$	597				$	713
	Transaction costs	—					468
	Net operating loss and tax credit carry-forwards	74,616					33,942
	Prepaid expenses	1,094					2,618
	Accrued expenses	—					4,789
	Deferred revenue	—					4,002
	Goodwill	42,726					—
	Deferred rent	1,121					—
	Other	1,197					575
	Total deferred tax assets	121,351					47,107
	Other identifiable intangible assets	(125,652		)			(134,097		)
	Goodwill	—					(7,049		)
	Trade and other receivables	(2,224		)			(1,478		)
	Debt exchange	(5,585		)			—
	Other long-lived assets	(10,406		)			(12,510		)
	Other	(222		)			—
	Total deferred tax liabilities	(144,089		)			(155,134		)
	Net deferred tax liabilities	$	(22,738	)			$	(108,027	)
Schedule of Effective Income Tax Rate Reconciliation	'
	A reconciliation of the statutory U.S. federal income tax rate to the Company’s effective tax rate is as follows:
		Successor				Predecessor
		Years ended December 31, 2013	From inception (April 20, 2012) to December 31, 2012			January 1, 2012 to June 6, 2012	Years ended December 31, 2011
	Income taxes at federal statutory rate	35.00%	35.00%			35.00%	35.00%
	State and local tax	2.1	3			3.2	4
	Foreign rate differential	0.1	—			—	—
	State rate changes	-0.7	—			—	—
	Non-deductible transaction expenses	—	-2			—	—
	Goodwill impairment charge	-17	—			—	—
	Research tax credit	0.2	—			—	-0.7
	Other permanent items	—	-0.3			0.4	1.6
	Effective rate	19.70%	35.70%			38.60%	39.90%

Commitment_and_Contingencies_T

Commitment and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases	'
	Future minimum lease payments under these operating leases are as follows:
	For the period ending December 31,
	2014	$	10,600
	2015	9,928
	2016	9,258
	2017	5,250
	2018	4,314
	Thereafter	9,790
		$	49,140
Schedule of Future Minimum Lease Payments for Capital Leases	'
	Future minimum lease payments under these capital leases are as follows:
	For the period ending December 31,
	2014	$	1,731
	2015	759
	2016	759
	2017	759
	2018 and thereafter	—
	Total future minimum lease payments	$	4,008
	Less imputed interest	309
	Present value of future minimum lease payments	$	3,699

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information	'
	Segment information for the Successor Periods December 31, 2013, from inception (April 20, 2012) to December 31, 2012, and for the Predecessor Period January 1, 2012 to June 6, 2012, and for the Predecessor Period December 31, 2011 is as follows:
		Year ended December 31, 2013
		Successor
		Revenues			Depreciation			Segment
					and			Operating
					Amortization(1)			Income
								(Expense) (3)
	Payer	$	259,341		$	26,670		$	38,158
	Hospitals	123,692			15,301			16,646
	Clinicians	109,669			11,142			30,655
	Segment totals	492,702			53,113			85,459
	Center/Other(2)	—			—			(8,610		)
		$	492,702		$	53,113		$	76,849
		From inception (April 20, 2012) to December 31, 2012
		Successor
		Revenues			Depreciation			Segment
					and			Operating
					Amortization(1)			Income
								(Expense) (3)
	Payer	$	136,922		$	10,978		$	27,060
	Hospitals	59,300			6,352			4,353
	Clinicians	45,563			4,840			3,231
	Segment totals	241,785			22,170			34,644
	Center/Other(2)	1			—			-586
		$	241,786		$	22,170		$	34,058
		January 1 to June 6, 2012
		Predecessor
		Revenues			Depreciation			Segment
					and			Operating
					Amortization(1)			Income
								(Expense) (3)
	Payer	$	106,482		$	9,539		$	15,411
	Hospitals	53,236			5,520			8,222
	Clinicians	49,277			4,206			14,347
	Segment totals	208,995			19,265			37,980
	Center/Other(2)	3			—			(23,390		)
		$	208,998		$	19,265		$	14,590
		Year ended December 31, 2011
		Predecessor
		Revenues			Depreciation and Amortization(1)			Segment
								Operating
								Income
								(Expense) (3)
	Payer	$	245,065		$	23,795		$	37,378
	Hospitals	124,980			9,323			29,231
	Clinicians	111,672			5,941			33,746
	Segment totals	481,717			39,059			100,355
	Center/Other(2)	1,490			—			(35,993		)
		$	483,207		$	39,059		$	64,362
	(1)    Depreciation and amortization expense includes the depreciation of hardware and other tangible assets and the amortization of developed technology and content, but excludes the amortization of other identifiable intangible assets because the CODM during both the Predecessor and Successor Periods did not consider this item when allocating resources and assessing performance.
	(2)    Center/Other costs consist of items that are not directly attributable to reportable segments, revenue of discontinued product, marketing, technical support, executive, administrative costs and allocations from the Predecessor Parent. Center/Other includes the elimination of inter company transactions.
	(3)    Segment operating income (expense) excludes goodwill impairment charge because the CODM does not consider this item when allocating resources and assessing performance.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	'
	The following table reconciles segment operating income per the reportable segment information to loss before income taxes per the consolidated and combined statements of comprehensive loss.
		Year ended December 31,				From inception (April 20, 2012) to December 31,					January 1, 2012 to June 6,			Year ended December 31,
		2013				2012					2012			2011
		Successor									Predecessor
	Segment operating income	$	76,849			$	34,058				$	14,590		$	64,362
	Amortization of other identifiable intangible assets	(34,460		)		(19,527		)			(8,226		)	(19,691		)
	Goodwill impairment	(366,662		)		—					—			—
	Other operating expenses	(35,038		)		(49,622		)			(18,803		)	(20,002		)
	Operating income (loss)	(359,311		)		(35,091		)			(12,439		)	24,669
	Interest expense to Predecessor Parent	—				—					—			134
	Interest income	—				—					3			—
	Interest expense	(70,581		)		(49,014		)			—			(63		)
	Other finance costs	(24		)		—					—			—
	Income (loss) before income taxes	$	(429,916	)		$	(84,105	)			$	(12,436	)	$	24,740

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Costs allocations to the Company from Predecessor	'
	The amounts allocated to the Company for the period ended June 6, 2012 are presented in the combined statement of comprehensive income (loss) as follows:
		January 1, 2012 to June 6, 2012		Year ended December 31, 2011
	Cost of revenues, excluding depreciation and amortization	$	4,868	$	10,213
	Allocation of costs from Predecessor Parent and affiliates	10,003		34,496
		$	14,871	$	44,709

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Carrying amounts and fair values of the Term Loan Facility	'
	At December 31, 2013, the carrying amounts and fair values of the Senior Credit Facility, Revolving Credit Facility and 10.625% Senior Notes were as follows:
				Fair values
		Carrying amounts		Level 1		Level 2		Level 3
	Senior Term Loan	$	516,831	$	—	$	531,625	$	—
	Revolver	30,000		—		30,000		—
	10.625% Senior Notes	325,427		—		369,876		—
	At December 31, 2012, the carrying amounts and fair values of the Senior Term Loan and 10.625% Senior Notes were as follows:
				Fair values
		Carrying amounts		Level 1		Level 2		Level 3
	Senior Term Loan	$	512,813	$	—	$	528,242	$	—
	10.625% Senior Notes	325,159		—		348,415		—

Supplemental_condensed_financi1

Supplemental condensed financial information of the Parent Company (Tables)	12 Months Ended
	Dec. 31, 2013
Condensed Financial Information of Parent Company Only Disclosure [Abstract]	'
Parent Company Condensed Balance Sheet	'
	Parent Company Condensed Balance Sheet
	(in thousands of dollars, unless otherwise indicated)
		As of December 31,
		2013			2012
	Asset
	Investments in Truven Health Analytics Inc.	$	79,283		$	419,252
	Total assets	79,283			419,252
	Liabilities and Equity
	Total liabilities	—			—
	Equity
	Common stock—$0.01 par value; 1,000 shares authorized, 1 share issued and outstanding at December 31, 2013 and 2012	—			—
	Additional paid in capital	478,549			473,364
	Accumulated deficit	(399,101		)	(54,112		)
	Currency translation adjustment	(165		)	—
	Total liabilities and stockholders’ equity	$	79,283		$	419,252
	The accompanying notes are an integral part of these condensed financial statements.
Parent Company Condensed Statement of Comprehensive Loss	'
	Parent Company Condensed Statement of Comprehensive Loss
	(in thousands of dollars, unless otherwise indicated)
		For the year ended December 31, 2013			From inception (April 20, 2012) to December 31, 2012
	Revenues, net	$	—		$	—
	Operating costs and expenses	—			—
	(Loss) income before income taxes	—			—
	Benefit from (provision for) income taxes	—			—
	Income before share in net loss from subsidiaries	—			—
	Share of net loss from subsidiaries	(344,989		)	(54,112		)
	Net loss	$	(344,989	)	$	(54,112	)
	Other comprehensive loss:
	Foreign currency translation adjustments	$	(165	)	$	—
	Total comprehensive loss	$	(345,154	)	$	(54,112	)
	The accompanying notes are an integral part of these condensed financial statements.
Parent Company Condensed Statement of Cash Flows	'
	Parent Company Condensed Statement of Cash Flows
	(in thousands of dollars, unless otherwise indicated)
		For the year ended December 31, 2013			From inception (April 20, 2012) to December 31, 2012
	Net cash provided by operating activities	$	—		$	—
	Cash flows from investing activities:
	Investment in Truven Health Analytics, Inc.	(2,350		)	(464,400		)
	Net cash used in investing activities	(2,350		)	(464,400		)
	Cash flows from financing activities:
	Issuance of common stock	—			464,400
	Additional capital contribution	2,350			—
	Net cash provided by financing activities	2,350			464,400
	Change in cash and cash equivalents	—			—
	Cash and cash equivalents at the beginning of the period	—			—
	Cash and cash equivalents at the end of the period	$	—		$	—
	The accompanying notes are an integral part of these condensed financial statements.

Description_of_Business_and_Ba2

Description of Business and Basis of Presentation Narrative (Details) (USD $)	9 Months Ended		5 Months Ended	12 Months Ended	5 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2012	Jun. 06, 2012	Dec. 31, 2011	Jun. 06, 2012	Dec. 31, 2011	Jun. 06, 2012
	Cost of Revenues	Selling and Marketing Expense	Predecessor	Predecessor	Predecessor	Predecessor	Thomson Reuters (Healthcare) Inc. (TRHI)
			Cost of Revenues	Cost of Revenues	Selling and Marketing Expense	Selling and Marketing Expense
Business Acquisition [Line Items]	'	'	'	'	'	'	'
Percentage of equity interests acquired by Wolverine	'	'	'	'	'	'	100.00%
Prior period reclassified facilities costs	$4.50	$0.50	$3.30	$7.30	$0.40	$0.80	'

Description_of_Business_and_Ba3

Description of Business and Basis of Presentation Prior Period Adjustments (Details) (USD $)

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Operating Segments

Operating Segments

Center

Center

Reportable Segments

Reportable Segments

Payer

Payer

Hospitals

Hospitals

Clinicians

Clinicians

Successor

Successor

Successor

Successor

Successor

Successor

Successor

Successor

Successor

Successor

Successor

Successor

Successor

Successor

Successor

Successor

Successor

Successor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Center

Reportable Segments

Payer

Hospitals

Clinicians

As Reported

As Reported

As Reported

As Reported

As Reported

As Reported

Adjustments

Adjustments

Adjustments

Adjustments

Adjustments

Adjustments

Operating Segments

Operating Segments

Center

Center

Reportable Segments

Reportable Segments

Payer

Payer

Hospitals

Hospitals

Clinicians

Clinicians

As Reported

As Reported

As Reported

As Reported

As Reported

As Reported

As Reported

As Reported

As Reported

As Reported

As Reported

As Reported

Adjustments

Adjustments

Adjustments

Adjustments

Adjustments

Adjustments

Adjustments

Adjustments

Adjustments

Adjustments

Adjustments

Adjustments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Center

Reportable Segments

Payer

Hospitals

Clinicians

Operating Segments

Center

Reportable Segments

Payer

Hospitals

Clinicians

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Center

Center

Reportable Segments

Reportable Segments

Payer

Payer

Hospitals

Hospitals

Clinicians

Clinicians

Operating Segments

Operating Segments

Center

Center

Reportable Segments

Reportable Segments

Payer

Payer

Hospitals

Hospitals

Clinicians

Clinicians

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Depreciation and Amortization

'

'

$22,170

[1]

$53,113

[1]

$0

[1],[2]

$0

[1],[2]

$22,170

[1]

$53,113

[1]

$10,978

[1]

$26,670

[1]

$6,352

[1]

$15,301

[1]

$4,840

[1]

$11,142

[1]

$22,170

$0

$22,170

$10,978

$6,352

$4,840

$20,837

$1,333

$22,170

$10,276

$6,983

$3,578

$1,333

($1,333)

$0

$702

($631)

$1,262

'

'

$19,265

[1]

$39,059

[1]

$0

[1],[2]

$0

[1],[2]

$19,265

[1]

$39,059

[1]

$9,539

[1]

$23,795

[1]

$5,520

[1]

$9,323

[1]

$4,206

[1]

$5,941

[1]

$18,245

$36,319

$1,020

$2,740

$19,265

$39,059

$8,249

$22,430

$6,516

$8,535

$3,480

$5,354

$1,020

$2,740

($1,020)

($2,740)

$0

$0

$1,290

$1,365

($996)

$788

$726

$587

Segment operating income (loss)

($35,091)

($359,311)

$34,644

[3]

$85,459

[3]

($586)

[2],[3]

($8,610)

[2],[3]

$34,058

[3]

$76,849

[3]

$27,060

[3]

$38,158

[3]

$4,353

[3]

$16,646

[3]

$3,231

[3]

$30,655

[3]

$34,644

($586)

$34,058

$27,060

$4,353

$3,231

$35,977

($1,919)

$34,058

$27,762

$3,722

$4,493

($1,333)

$1,333

$0

($702)

$631

($1,262)

($12,439)

$24,669

$37,980

[3]

$100,355

[3]

($23,390)

[2],[3]

($35,993)

[2],[3]

$14,590

[3]

$64,362

[3]

$15,411

[3]

$37,378

[3]

$8,222

[3]

$29,231

[3]

$14,347

[3]

$33,746

[3]

$39,000

$103,095

($24,410)

($38,733)

$14,590

$64,362

$16,701

$38,743

$7,226

$30,019

$15,073

$34,333

($1,020)

($2,740)

$1,020

$2,740

$0

$0

($1,290)

($1,365)

$996

($788)

($726)

($587)

[1]

Depreciation and amortization expense includes the depreciation of hardware and other tangible assets and the amortization of developed technology and content, but excludes the amortization of other identifiable intangible assets because the CODM during both the Predecessor and Successor Periods did not consider this item when allocating resources and assessing performance.

[2]

Center/Other costs consist of items that are not directly attributable to reportable segments, revenue of discontinued product, marketing, technical support, executive, administrative costs and allocations from the Predecessor Parent. Center/Other includes the elimination of inter company transactions.

[3]

Segment operating income (expense) excludes goodwill impairment charge because the CODM does not consider this item when allocating resources and assessing performance.

Significant_Accounting_Policie3

Significant Accounting Policies - Expenses (Details) (USD $)	9 Months Ended	12 Months Ended	5 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2013	Jun. 06, 2012	Dec. 31, 2011
			Predecessor	Predecessor
Schedule of Operating Expenses [Line Items]	'	'	'	'
Advertising expense	$2,153	$2,753	$1,018	$3,313
Research and development expense	$534	$1,704	$1,586	$6,605

Significant_Accounting_Policie4

Significant Accounting Policies - Narrative (Details) (USD $)	9 Months Ended	12 Months Ended	5 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2013	Jun. 06, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
			Predecessor	Predecessor	Customer Concentration Risk	Customer Concentration Risk	Customer Concentration Risk
					Accounts Receivable	Accounts Receivable	Revenue
					customer	customer	Predecessor
							Payer
							Customer One
							customer
Concentration Risk [Line Items]	'	'	'	'	'	'	'
Number of customers	'	'	'	'	0	0	1
Revenues, net	$241,786	$492,702	$208,998	$483,207	'	'	$52,985
Concentration percentage	'	'	'	'	'	'	11.00%
Note receivable term	'	'1 year	'	'	'	'	'
Interest rate spread on receivable from Predecessor Parent	'	0.75%	'	'	'	'	'
Amortization of debt issuance costs	1,626	2,557	0	0	'	'	'
Unamortized deferred financing costs	$17,409	$13,902	'	'	'	'	'

Significant_Accounting_Policie5

Significant Accounting Policies - Property and Equipment, Useful Lives (Details)	12 Months Ended
	Dec. 31, 2013
Minimum | Computer hardware	'
Property, Plant and Equipment [Line Items]	'
Expected useful life	'3 years
Minimum | Furniture, fixtures and equipment	'
Property, Plant and Equipment [Line Items]	'
Expected useful life	'5 years
Maximum | Computer hardware	'
Property, Plant and Equipment [Line Items]	'
Expected useful life	'5 years
Maximum | Furniture, fixtures and equipment	'
Property, Plant and Equipment [Line Items]	'
Expected useful life	'7 years

Significant_Accounting_Policie6

Significant Accounting Policies - Intangible Assets, Useful Lives (Details)	9 Months Ended	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2013
Developed technology and content | Minimum	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful life	'	'3 years
Developed technology and content | Maximum	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful life	'	'10 years
Trade names	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful life	'	'15 years
Customer relationships	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful life	'11 years 6 months	'11 years 6 months
Customer relationships | Minimum	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful life	'	'11 years
Customer relationships | Maximum	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Estimated useful life	'	'12 years

Acquisition_Details

Acquisition (Details) (USD $)

0 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

Jun. 06, 2012

Dec. 31, 2012

Dec. 31, 2013

Jun. 06, 2012

Jun. 06, 2012

Jun. 06, 2013

Jun. 06, 2012

Jun. 06, 2013

Jun. 06, 2012

Jun. 06, 2012

Jun. 06, 2013

Jun. 06, 2013

Term Loan

Senior Notes

Thomson Reuters (Healthcare) Inc. (TRHI)

Thomson Reuters (Healthcare) Inc. (TRHI)

Thomson Reuters (Healthcare) Inc. (TRHI)

Thomson Reuters (Healthcare) Inc. (TRHI)

Thomson Reuters (Healthcare) Inc. (TRHI)

Thomson Reuters (Healthcare) Inc. (TRHI)

Thomson Reuters (Healthcare) Inc. (TRHI)

Trademarks and trade names

Trademarks and trade names

Customer relationships

Customer relationships

Customer relationships

Minimum

Maximum

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Net cash consideration

'

$1,249,402,000

$0

'

'

'

$1,249,402,000

'

'

'

'

'

Direct costs associated with business acquisition

'

'

'

'

'

'

26,734,000

'

'

'

'

'

Common equity contributed

464,400,000

464,400,000

0

'

'

'

'

'

'

'

'

'

Term loan facility principal amount

'

'

'

527,625,000

327,150,000

'

'

'

'

'

'

'

Adjustment to goodwill due to purchases

'

'

'

'

'

533,000

'

'

'

'

'

'

Finalization of acquisition valuation adjustment, current assets

'

'

'

'

'

458,000

'

'

'

'

'

'

Finalization of acquisition valuation adjustment, non-current assets

'

'

'

'

'

120,000

'

'

'

'

'

'

Finalization of acquisition valuation adjustment, noncurrent deferred tax liabilities

'

'

'

'

'

45,000

'

'

'

'

'

'

Other identifiable intangible assets

'

'

'

'

'

'

416,000,000

'

86,200,000

329,800,000

'

'

Weighted average useful life

'

'

'

'

'

'

'

'15 years

'

'

'11 years

'12 years

Goodwill not tax deductible

'

'

'

'

'

'

465,600,000

'

'

'

'

'

Tax deductible goodwill

'

'

'

'

'

'

358,700,000

'

'

'

'

'

Tax deductible goodwill from asset purchase

'

'

'

'

'

'

129,900,000

'

'

'

'

'

Tax deductible goodwill, historical basis Thomson Reuters

'

'

'

'

'

'

$228,800,000

'

'

'

'

'

Acquisition_Summary_of_The_Fin

Acquisition Summary of The Final Allocation of Purchase Price (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Apr. 20, 2012	Jun. 06, 2012
In Thousands, unless otherwise specified				Thomson Reuters (Healthcare) Inc. (TRHI)
Business Acquisition [Line Items]	'	'	'	'
Trade and other receivables	'	'	'	$77,598
Prepaid assets and other current assets	'	'	'	11,973
Computer hardware and other property	'	'	'	24,693
Developed technology and content	'	'	'	159,622
Other identifiable intangible assets	'	'	'	416,000
Other noncurrent assets	'	'	'	106
Current deferred tax assets	'	'	'	11,262
Current liabilities	'	'	'	-46,588
Deferred revenue	'	'	'	-80,239
Noncurrent deferred tax liabilities	'	'	'	-149,364
Net assets acquired	'	'	'	425,063
Goodwill on acquisition	457,677	824,339	0	824,339
Net consideration paid in cash	'	'	'	$1,249,402

Acquisition_Pro_Forma_Details

Acquisition Pro Forma (Details) (Thomson Reuters (Healthcare) Inc. (TRHI), USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Thomson Reuters (Healthcare) Inc. (TRHI)	'	'
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]	'	'
Revenues, net	$490,625	$435,918
Net loss	($11,173)	($52,462)

Trade_and_other_receivables_De

Trade and other receivables (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Receivables [Abstract]	'	'
Trade receivables, gross	$99,011	$106,699
Less: Allowance for doubtful accounts	-1,530	-1,865
Trade receivables, net	97,481	104,834
Other receivables	317	307
Trade and other receivables, net	$97,798	$105,141
Interest rate	1.93%	'
Percentage of redemption price on notes (in percent)	100.00%	'

Prepaid_and_other_current_asse2

Prepaid and other current assets (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'	'
Royalties	$3,502	$3,559
Commissions and distribution fees	9,046	5,618
Services, licenses and maintenance	10,720	8,388
Others	940	844
Prepaid expenses and other current assets	$24,208	$18,409

Computer_hardware_and_other_pr2

Computer hardware and other property (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Computer hardware and other property, gross	$75,312	$47,025
Accumulated depreciation	-27,275	-6,834
Computer hardware and other property, net	48,037	40,191
Computer hardware	'	'
Property, Plant and Equipment [Line Items]	'	'
Computer hardware and other property, gross	67,285	40,494
Accumulated depreciation	-24,762	-5,929
Computer hardware and other property, net	42,523	34,565
Building and leasehold improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Computer hardware and other property, gross	5,166	3,106
Accumulated depreciation	-1,124	-393
Computer hardware and other property, net	4,042	2,713
Furniture, fixtures and equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Computer hardware and other property, gross	2,861	3,425
Accumulated depreciation	-1,389	-512
Computer hardware and other property, net	$1,472	$2,913

Developed_technology_and_conte2

Developed technology and content (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Developed technology and content, gross	$416,000	$416,000
Accumulated amortization	-53,986	-19,527
Net	362,014	396,473
Developed technology and content	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Developed technology and content, gross	195,961	175,828
Accumulated amortization	-47,324	-15,493
Net	$148,637	$160,335

Goodwill_Details

Goodwill (Details) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Goodwill [Roll Forward]	'	'	'
Beginning balance	'	$0	$824,339
Acquisition (see Note 3)	'	824,339	'
Impairment charge	-366,662	0	-366,662
Ending balance	457,677	824,339	457,677
Payer	'	'	'
Goodwill [Roll Forward]	'	'	'
Beginning balance	'	0	414,992
Acquisition (see Note 3)	'	414,992	'
Impairment charge	'	'	-207,918
Ending balance	207,074	414,992	207,074
Hospitals	'	'	'
Goodwill [Roll Forward]	'	'	'
Beginning balance	'	0	206,312
Acquisition (see Note 3)	'	206,312	'
Impairment charge	'	'	-65,792
Ending balance	140,520	206,312	140,520
Clinicians	'	'	'
Goodwill [Roll Forward]	'	'	'
Beginning balance	'	0	203,035
Acquisition (see Note 3)	'	203,035	'
Impairment charge	'	'	-92,952
Ending balance	$110,083	$203,035	$110,083

Goodwill_Narrative_Details

Goodwill - Narrative (Details) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended	0 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Nov. 01, 2013	Nov. 01, 2013	Nov. 01, 2013	Nov. 01, 2013
				Minimum	Maximum	Combined Income Approach	Market Approach
Goodwill [Line Items]	'	'	'	'	'	'	'
Discount rate	'	'	'	11.60%	13.40%	'	'
Weighted valuation percentage	'	'	'	'	'	70.00%	30.00%
Goodwill impairment	$366,662	$0	$366,662	'	'	'	'

Other_identifiable_intangible_2

Other identifiable intangible assets (Details) (USD $)	9 Months Ended	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2013
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Cost	$416,000,000	$416,000,000
Accumulated amortization	-19,527,000	-53,986,000
Net	396,473,000	362,014,000
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]	'	'
2014	'	34,500,000
2015	'	34,500,000
2016	'	34,500,000
2017	'	34,500,000
2018	'	34,500,000
Customer relationships	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Average life (years)	'11 years 6 months	'11 years 6 months
Cost	329,800,000	329,800,000
Accumulated amortization	-16,270,000	-44,983,000
Net	313,530,000	284,817,000
Trademarks and trade names	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Average life (years)	'15 years	'15 years
Cost	86,200,000	86,200,000
Accumulated amortization	-3,257,000	-9,003,000
Net	$82,943,000	$77,197,000

Accounts_payable_and_accrued_e2

Accounts payable and accrued expenses (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Accounts payable - trade	$26,259	$48,691
Accrued employee compensation	13,529	23,953
Accrued royalties	3,773	3,793
Accrued professional fees	4,409	8,658
Accrued interest	2,966	3,367
Customer deposits	618	806
Other accrued expenses	1,822	3,239
Accounts payable and accrued expenses	$53,376	$92,507

Schedule_of_Longterm_Debt_Deta

Schedule of Long-term Debt (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Long-term debt	$872,258	$837,972
Current portion of long-term debt	5,350	5,276
Long-term debt excluding current maturities	866,908	832,696
Senior Credit Facility Due 2019 | Secured Debt | Term Loan	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	516,831	512,813
Senior Credit Facility Due 2019 | Revolving Credit Facility | Line of Credit	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	30,000	0
Senior Note due 2020 | Senior Notes	'	'
Debt Instrument [Line Items]	'	'
Long-term debt	$325,427	$325,159

Longterm_Debt_Parenthetical_De

Long-term Debt Parenthetical (Details) (USD $)	Oct. 03, 2012	Dec. 31, 2013	Dec. 31, 2012	Jun. 06, 2012	Dec. 31, 2013	Apr. 26, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Senior Credit Facility Due 2019	Senior Notes	Senior Notes	Senior Notes	Secured Debt	Secured Debt	Secured Debt
		Senior Note due 2020	Senior Note due 2020	Senior Note due 2020	Term Loan	Term Loan	Term Loan
					Senior Credit Facility Due 2019	Senior Credit Facility Due 2019	Senior Credit Facility Due 2019
Debt Instrument [Line Items]	'	'	'	'	'	'	'
Debt instrument original issue discount	$5,200	$1,723	$1,991	'	$14,156	$5,800	$12,174
Stated interest rate on Senior Notes (in percent)	'	10.63%	10.63%	10.63%	'	'	'

Longterm_Debt_Narrative_Detail

Long-term Debt Narrative (Details) (USD $)

9 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

Dec. 31, 2012

Dec. 31, 2013

Jun. 06, 2012

Jun. 06, 2012

Apr. 26, 2013

Oct. 03, 2012

Apr. 30, 2013

Dec. 31, 2012

Apr. 26, 2013

Apr. 26, 2013

Apr. 26, 2013

Apr. 26, 2013

Apr. 26, 2013

Dec. 31, 2013

Dec. 31, 2013

Apr. 26, 2013

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2013

Apr. 24, 2013

Dec. 31, 2012

Apr. 26, 2013

Dec. 31, 2013

Feb. 14, 2014

Dec. 31, 2013

Jun. 06, 2012

Jun. 06, 2012

Dec. 31, 2013

Dec. 31, 2012

Jun. 06, 2012

Jun. 06, 2012

Jun. 06, 2012

Jun. 06, 2012

Dec. 31, 2013

Term Loan

Senior Notes

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Note due 2020

Senior Note due 2020

Senior Note due 2020

Senior Note due 2020

Senior Note due 2020

Senior Note due 2020

Senior Note due 2020

Senior Note due 2020

Senior Note due 2020

Senior Notes, Series A Due 2020

Prime Rate

Federal Funds Purchased

One Month Eurodollar

Eurodollar

Revolving Credit Facility

Revolving Credit Facility

Letter of Credit

Term Loan

Term Loan

Term Loan

Term Loan

Term Loan

Term Loan

Line of Credit

Line of Credit

Line of Credit

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Senior Notes

Secured Debt

Secured Debt

Secured Debt

Secured Debt

Secured Debt

Secured Debt

Revolving Credit Facility

Revolving Credit Facility

Revolving Credit Facility

Prior to June 1, 2016

On or after June 1, 2016

One or after June 1, 2018

Prior to June 1, 2015

Subsequent Event

Line of Credit Facility [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior credit facility maximum borrowing capacity

'

'

'

'

$585,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Term loan facility principal amount

'

'

527,625,000

327,150,000

'

'

'

'

'

'

'

'

'

'

'

535,000,000

'

'

'

523,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit Facility maturity term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'7 years

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding letters of credit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

30,000,000

'

'

'

'

'

'

'

'

'

'

'

Revolving credit facility remaining borrowing capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

19,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prime rate

'

'

'

'

'

'

'

'

'prime rate

'federal funds

'one month Eurodollar rate

'Eurodollar

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Basis spread on variable rate (in percent)

'

'

'

'

'

'

'

'

'

0.50%

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum base rate (in percent)

'

'

'

'

2.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum Eurodollar base rate (in percent)

'

'

'

'

1.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revolving credit facility commitment fee on unused capacity (in percent)

'

'

'

'

'

'

'

'

'

'

'

'

0.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Quarterly payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,300,000

1,337,500

1,319,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Frequency of periodic payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'quarterly

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction of the applicable margin from refinancing (in percent)

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

1.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repricing call protection (in percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on extinguishment of debt

5,110,000

2,353,000

'

'

'

'

'

6,700,000

'

'

'

'

'

'

'

3,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Lenders fees associated with refinancing

'

'

'

'

'

6,700,000

6,700,000

'

'

'

'

'

'

'

'

6,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument original issue discount

'

'

'

'

'

5,200,000

'

'

'

'

'

'

'

'

'

5,800,000

14,156,000

'

14,156,000

'

12,174,000

'

'

'

'

'

'

1,723,000

1,991,000

'

'

'

'

'

Lenders fee expensed

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Third party legal costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt extinguished costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayment of long-term debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000,000

'

'

'

'

'

'

'

'

'

'

Stated interest rate on Senior Notes (in percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.63%

10.63%

10.63%

'

'

'

'

10.63%

Percentage of redemption price on notes (in percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

101.00%

'

'

100.00%

105.31%

100.00%

110.63%

'

Maximum redemption percentage of aggregate principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35.00%

'

Additional penalty interest per annum for the 90 day period (in percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.25%

'

'

'

'

'

'

'

'

Additional penalty interest per annum for each subsequent 90 day period (in percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.25%

'

'

'

'

'

'

'

'

Maximum additional penalty interest per annum (in percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

Additional penalty interest incurred and accrued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$463,500

'

'

'

'

'

'

'

'

'

Maturities_of_Longterm_Debt_De

Maturities of Long-term Debt (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'
2014	$5,350
2015	5,350
2016	5,350
2017	35,350
2018	5,350
Thereafter	810,158
Total long-term debt maturities	$866,908

Employee_benefit_plans_Details

Employee benefit plans (Details) (USD $)	9 Months Ended	12 Months Ended	5 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2013	Jun. 06, 2012	Dec. 31, 2011
			Predecessor	Predecessor
Defined Contribution Plan Disclosure [Line Items]	'	'	'	'
Defined contribution plan, vesting period	'	'	'4 years	'
Cost recognized	$3,294	$6,975	$3,091	$5,747
Pension expense	'	'	$159	$364

Sharebased_Compensation_Detail

Share-based Compensation (Details) (USD $)

9 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

In Thousands, except Share data, unless otherwise specified

Dec. 31, 2012

Dec. 31, 2013

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Jun. 06, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Successor

Successor

plan

Maximum

TRSUs

TRSUs

TRSUs

PRSUs

PRSUs

PRSUs

PRSUs

Class B Membership Interest

Class B Membership Interest

Maximum

Maximum

Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum number of shares authorized for issuance

'

'

'

50,000,000

'

'

'

'

'

'

'

'

'

'

Shares available for future issuance

'

'

'

19,292,115

'

'

'

'

'

'

'

'

'

'

Share-based compensation expense

'

'

$2,519

$1,105

'

'

'

'

'

'

'

'

'

'

Tax benefits recognized

'

'

972

441

'

'

'

'

'

'

'

'

'

'

Share-based compensation expense due to accelerated vesting

'

'

1,464

'

'

'

'

'

'

'

'

'

'

'

Expiration period (in years)

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

Exercises in period

'

'

0

4,230

'

'

'

'

'

'

'

'

'

'

Cash received from exercise of stock options

'

'

'

113

'

'

'

'

'

'

'

'

'

'

Fair value of vested options

'

'

2,725

85

'

'

'

'

'

'

'

'

'

'

Fair value of vested awards

'

'

'

'

'

1,061

2,381

'

3,220

231

'

'

'

1,121

Percentage of awards that may vest

'

'

'

'

'

'

'

'

'

'

200.00%

0.00%

'

'

Employee stock purchase plan, purchase price discount

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

Employee stock purchase plan discount expense

'

'

139

298

'

'

'

'

'

'

'

'

'

'

Number of share-based payment plan related to the plans administered by our Predecessor

'

'

0

'

'

'

'

'

'

'

'

'

'

'

Maximum percentage of Membership Interest can be awarded to executive officers

'

'

'

'

'

'

'

'

'

'

'

'

'

6.25%

Vesting percentage on each of the first five anniversaries (in percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

Award vesting period (in years)

'

'

'

'

'

'

'

'7 years

'

'

'

'

'

'5 years

Vesting percentage upon change in control of company

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

Compensation expense recognized against additional paid in capital

329

1,457

'

'

'

'

'

'

'

'

'

'

329

1,457

Estimated forfeiture rate (in percent)

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

10.00%

Period in which Class B Membership Interest expected to be recognized (in years)

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years 6 months

Total unrecognized compensation costs

'

'

'

'

'

'

'

'

'

'

'

'

'

$4,062

Percent of Class B Membership Interest vested

'

'

'

'

'

'

'

'

'

'

'

'

'

0.80%

Sharebased_Compensation_Vestin

Share-based Compensation Vesting Periods (Details) (Predecessor, Maximum)	5 Months Ended
	Jun. 06, 2012
Stock Options	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Award vesting period (in years)	'4 years
TRSUs	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Award vesting period (in years)	'7 years
PRSUs	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Performance period (in years)	'3 years

Sharebased_Compensation_Assump

Share-based Compensation Assumptions Used (Details) (Predecessor, USD $)	5 Months Ended	12 Months Ended
	Jun. 06, 2012	Dec. 31, 2011
Predecessor	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted average grant date fair value	$5.21	$8.42
Exercise price	$28.42	$38.98
Risk-free interest rate	1.20%	2.70%
Dividend yield	3.40%	3.30%
Volatility factor	28.00%	29.00%
Expected life (in years)	'6 years	'6 years

Sharebased_Compensation_Stock_

Share-based Compensation Stock Transactions (Details) (Predecessor, USD $)	5 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 06, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'
Beginning balance, Outstanding, Shares	270,753	'
Granted, shares	90,520	'
Ending balance, Outstanding, Shares	361,273	270,753
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]	'	'
Beginning balance, Outstanding, Weighted average exercise price (in dollars per share)	$34.16	'
Granted, Weighted average exercise price (in dollars per share)	$28.42	$38.98
Ending balance, Outstanding, Weighted average exercise price (in dollars per share)	$32.71	$34.16
Outstanding, Weighted average remaining contractual term	'	'7 years 4 months 17 days
Outstanding, Aggregate intrinsic value	$280	$182
TRSUs	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]	'	'
Beginning balance, Outstanding, Shares	28,748	'
Dividends accrued (in shares)	110	'
Granted (in shares)	0	'
Vested (in shares)	-24,829	'
Vested (accelerated) (in shares)	-4,029	'
Forfeited or expired (in shares)	0	'
Ending balance, Outstanding, Shares	0	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]	'	'
Beginning balance, Outstanding, Weighted average grant-date fair value (in dollars per share)	$36.75	'
Dividends accrued, Weighted average grant-date fair value (in dollars per share)	$0	'
Granted, Weighted average grant-date fair value (in dollars per share)	$0	'
Vested, Weighted average grant-date fair value (in dollars per share)	$36.48	'
Vested (acclerated), Weighted average grant-date fair value (in dollars per share)	$38.55	'
Forfeited or expired, Weighted average grant-date fair value (in dollars per share)	$0	'
Ending balance, Outstanding, Weighted average grant-date fair value (in dollars per share)	$0	'
PRSUs	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]	'	'
Beginning balance, Outstanding, Shares	148,949	'
Dividends accrued (in shares)	1,138	'
Granted (in shares)	67,740	'
Vested (in shares)	-41,016	'
Vested (accelerated) (in shares)	-63,834	'
Forfeited or expired (in shares)	-112,977	'
Ending balance, Outstanding, Shares	0	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]	'	'
Beginning balance, Outstanding, Weighted average grant-date fair value (in dollars per share)	$31.77	'
Dividends accrued, Weighted average grant-date fair value (in dollars per share)	$0	'
Granted, Weighted average grant-date fair value (in dollars per share)	$28.42	'
Vested, Weighted average grant-date fair value (in dollars per share)	$23.46	'
Vested (acclerated), Weighted average grant-date fair value (in dollars per share)	$35.37	'
Forfeited or expired, Weighted average grant-date fair value (in dollars per share)	$31.13	'
Ending balance, Outstanding, Weighted average grant-date fair value (in dollars per share)	$0	'

Sharebased_Compensation_Transa

Share-based Compensation Transaction Related to Class B Membership Interest (Details) (Class B Membership Interest, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Class B Membership Interest	'
Ownership Interests	'
Ownership interest percent, beginning period	4.10%
Ownership interest percent, granted	0.90%
Ownership interest percent, forfeited	-0.40%
Ownership interest percent, ending period	4.60%
Ownership interest percent, outstanding and vested	0.80%
Membership Interest, Fair Value at Grant Date	'
Membership interest fair value at grant date, beginning period	$5,714
Membership interest fair value at grant date, granted	1,162
Membership interest fair value at grant date, forfeited	-502
Membership interest fair value at grant date, ending period	6,374
Membership interest fair value at grant date, outstanding and vested	$1,143

Other_Operating_Expenses_Detai

Other Operating Expenses (Details) (USD $)	9 Months Ended	12 Months Ended	5 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2013	Jun. 06, 2012	Dec. 31, 2011
			Predecessor	Predecessor
Components of Other Operating Expenses [Line Items]	'	'	'	'
Disposal related costs	$0	$0	$9,818	$12,560
Severance and retention bonuses	10,184	3,808	7,741	6,768
Acquisition related costs	37,980	27,007	0	460
Asset write-offs (see Note 16)	0	1,294	0	0
Other	1,458	2,929	1,244	214
Total other operating expenses	$49,622	$35,038	$18,803	$20,002

Other_Operating_Expenses_Narra

Other Operating Expenses Narrative (Details) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended	0 Months Ended		2 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Mar. 31, 2012	Mar. 31, 2012	Jun. 06, 2012
				Minimum	Maximum	Predecessor
Components of Other Operating Expenses [Line Items]	'	'	'	'	'	'
Contingent payment period	'	'	'	'90 days	'1 year	'
Retention bonus in conjunction with the Acquisition	'	$8,635,000	$1,378,000	'	'	$5,800,000
Acquisition costs, data center migration and infrastructure	12,900,000	'	'	'	'	'
Acquisition costs, transitional services agreement	9,200,000	'	'	'	'	'
Acquisition costs, consulting and other professional services	4,900,000	'	'	'	'	'
Acquisition costs, transaction fees	'	12,000,000	'	'	'	'
Acquisition costs, finance fees	'	$26,000,000	'	'	'	'

Income_Taxes_Components_of_Inc

Income Taxes (Components of Income Tax Expense) (Details) (USD $)	9 Months Ended	12 Months Ended	5 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2013	Jun. 06, 2012	Dec. 31, 2011
			Predecessor	Predecessor
Income Tax [Line Items]	'	'	'	'
Federal	$0	$0	($4,807)	$3,174
State	82	235	-539	801
Foreign	0	236	0	0
Total current provision (benefit)	82	471	-5,346	3,975
Federal	-26,189	-75,817	477	5,353
State	-3,886	-9,472	66	531
Foreign	0	-109	0	0
Total deferred provision (benefit)	-30,075	-85,398	543	5,884
Total (benefit from) provision for income taxes	($29,993)	($84,927)	($4,803)	$9,859

Income_Taxes_Deferred_Tax_Asse

Income Taxes (Deferred Tax Assets and Liabilities) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'
Allowance for doubtful accounts and other reserves	$597	$713
Transaction costs	0	468
Net operating loss and tax credit carry-forwards	74,616	33,942
Prepaid expenses	1,094	2,618
Accrued expenses	0	4,789
Deferred revenue	0	4,002
Goodwill	42,726	0
Deferred rent	1,121	0
Other	1,197	575
Total deferred tax assets	121,351	47,107
Other identifiable intangible assets	-125,652	-134,097
Goodwill	0	-7,049
Trade and other receivables	-2,224	-1,478
Debt exchange	-5,585	0
Other long-lived assets	-10,406	-12,510
Other	-222	0
Total deferred tax liabilities	-144,089	-155,134
Net deferred tax liabilities	($22,738)	($108,027)

Income_Taxes_Deferred_Taxes_Ba

Income Taxes (Deferred Taxes Balance Sheet Classification) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'
Current deferred tax asset	$0	$10,648
Current deferred tax liabilities	-711	0
Noncurrent deferred tax liabilities	-22,027	-118,675
Net deferred tax liabilities	($22,738)	($108,027)

Income_Taxes_Operating_Loss_Ca

Income Taxes (Operating Loss Carryforwards) (Details) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Federal	'
Operating Loss Carryforwards [Line Items]	'
Operating Loss Carryforwards	$186.80
State	'
Operating Loss Carryforwards [Line Items]	'
Operating Loss Carryforwards	$171.70

Income_Taxes_Income_Tax_Reconc

Income Taxes (Income Tax Reconciliation) (Details)	9 Months Ended	12 Months Ended	5 Months Ended	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2013	Jun. 06, 2012	Dec. 31, 2011
			Predecessor	Predecessor
Income Tax [Line Items]	'	'	'	'
Income taxes at federal statutory rate	35.00%	35.00%	35.00%	35.00%
State and local tax	3.00%	2.10%	3.20%	4.00%
Foreign rate differential	0.00%	0.10%	0.00%	0.00%
State rate changes	0.00%	-0.70%	0.00%	0.00%
Non-deductible transaction expenses	-2.00%	0.00%	0.00%	0.00%
Goodwill impairment charge	0.00%	-17.00%	0.00%	0.00%
Research tax credit	0.00%	0.20%	0.00%	-0.70%
Other permanent items	-0.30%	0.00%	0.40%	1.60%
Effective rate	35.70%	19.70%	38.60%	39.90%

Commitment_and_Contingencies_F

Commitment and Contingencies Future Minimum Lease Payments (Details) (USD $)	9 Months Ended	12 Months Ended	5 Months Ended	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2013	Jun. 06, 2012	Dec. 31, 2011
			Predecessor	Predecessor
Operating Leases, Future Minimum Payments Due, Rolling Maturity [Abstract]	'	'	'	'
2014	'	$10,600,000	'	'
2015	'	9,928,000	'	'
2016	'	9,258,000	'	'
2017	'	5,250,000	'	'
2018	'	4,314,000	'	'
Thereafter	'	9,790,000	'	'
Total future minimum lease payments	'	49,140,000	'	'
Rent expense	$5,900,000	$11,100,000	$4,200,000	$9,500,000

Commitment_and_Contingencies_C

Commitment and Contingencies Capital Leases (Details) (USD $)	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Capital lease of computer hardware and other property net book value	$4,100,000
Capital lease of computer hardware and other property accumulated depreciation	400,000
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments, Fiscal Year Maturity [Abstract]	'
2014	1,731,000
2015	759,000
2016	759,000
2017	759,000
2018 and thereafter	0
Total future minimum lease payments	4,008,000
Less imputed interest	309,000
Present value of future minimum lease payments	$3,699,000

Contractual_Commitments_Detail

Contractual Commitments (Details) (USD $)	9 Months Ended	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2013
Long-term Purchase Commitment [Line Items]	'	'
Remaining balance of prepaid revenue share	$18,409,000	$24,208,000
Asset write-offs	0	1,294,000
Revenue Share with Supplier	'	'
Long-term Purchase Commitment [Line Items]	'	'
Payments of revenue sharing commitment	'	2,000,000
Remaining balance of prepaid revenue share	'	700,000
Minimum | Revenue Share with Supplier	'	'
Long-term Purchase Commitment [Line Items]	'	'
Revenue share minimum amount guaranteed by the Company in 2013	'	2,000,000
Revenue share minimum amount guaranteed by the Company in 2014	'	4,000,000
Revenue share minimum amount guaranteed by the Company in 2015	'	$6,000,000

Commitment_and_Contingencies_L

Commitment and Contingencies Litigation and Legal Proceedings (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Motion
Loss Contingencies [Line Items]	'
Number of dispositive motion to dismiss all the actions	1
Reglan Case	'
Loss Contingencies [Line Items]	'
Number of pharmaceutical tort lawsuits	225
Pacific Alliance Medical Center Case	'
Loss Contingencies [Line Items]	'
Amount medicare reimbursement denied	600,000

Segment_Information_Details

Segment Information (Details) (USD $)

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Segment

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Center, Other

Center, Other

Reportable Segments

Reportable Segments

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Predecessor

Payer

Payer

Hospitals

Hospitals

Clinicians

Clinicians

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Operating Segments

Center, Other

Center, Other

Reportable Segments

Reportable Segments

Payer

Payer

Hospitals

Hospitals

Clinicians

Clinicians

Segment Reporting [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of reportable segments

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

$241,785

$492,702

$136,922

$259,341

$59,300

$123,692

$45,563

$109,669

$1

[1]

$0

[1]

$241,786

$492,702

'

'

$208,995

$481,717

$106,482

$245,065

$53,236

$124,980

$49,277

$111,672

$3

[1]

$1,490

[1]

$208,998

$483,207

Depreciation and Amortization

'

'

22,170

[2]

53,113

[2]

10,978

[2]

26,670

[2]

6,352

[2]

15,301

[2]

4,840

[2]

11,142

[2]

0

[1],[2]

0

[1],[2]

22,170

[2]

53,113

[2]

'

'

19,265

[2]

39,059

[2]

9,539

[2]

23,795

[2]

5,520

[2]

9,323

[2]

4,206

[2]

5,941

[2]

0

[1],[2]

0

[1],[2]

19,265

[2]

39,059

[2]

Segment Operating Income (Expense)

($35,091)

($359,311)

$34,644

[3]

$85,459

[3]

$27,060

[3]

$38,158

[3]

$4,353

[3]

$16,646

[3]

$3,231

[3]

$30,655

[3]

($586)

[1],[3]

($8,610)

[1],[3]

$34,058

[3]

$76,849

[3]

($12,439)

$24,669

$37,980

[3]

$100,355

[3]

$15,411

[3]

$37,378

[3]

$8,222

[3]

$29,231

[3]

$14,347

[3]

$33,746

[3]

($23,390)

[1],[3]

($35,993)

[1],[3]

$14,590

[3]

$64,362

[3]

[1]

Center/Other costs consist of items that are not directly attributable to reportable segments, revenue of discontinued product, marketing, technical support, executive, administrative costs and allocations from the Predecessor Parent. Center/Other includes the elimination of inter company transactions.

[2]

Depreciation and amortization expense includes the depreciation of hardware and other tangible assets and the amortization of developed technology and content, but excludes the amortization of other identifiable intangible assets because the CODM during both the Predecessor and Successor Periods did not consider this item when allocating resources and assessing performance.

[3]

Segment operating income (expense) excludes goodwill impairment charge because the CODM does not consider this item when allocating resources and assessing performance.

Segment_Information_Reconcilia

Segment Information Reconciliation to Net Income (Loss) (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

5 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Dec. 31, 2011

Reportable Segments

Reportable Segments

Predecessor

Predecessor

Predecessor

Predecessor

Reportable Segments

Reportable Segments

Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]

'

'

'

'

'

'

'

'

'

Segment operating income (loss)

'

($35,091)

($359,311)

$34,058

[1]

$76,849

[1]

($12,439)

$24,669

$14,590

[1]

$64,362

[1]

Amortization of other identifiable intangible assets

'

-19,527

-34,460

'

'

-8,226

-19,691

'

'

Goodwill impairment

-366,662

0

-366,662

'

'

0

0

'

'

Other operating expenses

'

-49,622

-35,038

'

'

-18,803

-20,002

'

'

Operating income (loss)

'

-35,091

-359,311

34,058

[1]

76,849

[1]

-12,439

24,669

14,590

[1]

64,362

[1]

Net interest income from Predecessor Parent

'

0

0

'

'

0

134

'

'

Interest income

'

0

0

'

'

3

0

'

'

Interest Expense

'

-49,014

-70,581

'

'

0

-63

'

'

Other finance costs

'

0

-24

'

'

0

0

'

'

Income (loss) before income taxes

'

($84,105)

($429,916)

'

'

($12,436)

$24,740

'

'

[1]

Segment operating income (expense) excludes goodwill impairment charge because the CODM does not consider this item when allocating resources and assessing performance.

Related_Party_Cost_Allocations

Related Party Cost Allocations (Details) (Predecessor, Thomson Reuters, USD $)	5 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 06, 2012	Dec. 31, 2011
Predecessor | Thomson Reuters	'	'
Related Party Transaction [Line Items]	'	'
Cost of revenues, excluding depreciation and amortization	$4,868	$10,213
Allocation of costs from Predecessor Parent and affiliates	10,003	34,496
Total related party expenses	$14,871	$44,709

Related_Party_Transactions_Nar

Related Party Transactions Narrative (Details) (USD $)

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

5 Months Ended

12 Months Ended

0 Months Ended

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2013

Jun. 06, 2012

Dec. 31, 2011

Jun. 06, 2012

Thomson Reuters

Thomson Reuters

Thomson Reuters

Thomson Reuters U.S. Inc

Thomson Reuters U.S. Inc

Thomson Reuters U.S. Inc

Thomson Reuters U.S. Inc

Truven Holding Corp.

Predecessor

Predecessor

Predecessor

Transitional Service Agreement

Transitional Service Agreement

Reverse Transitional Services Agreement

Reverse Transitional Services Agreement

Reverse Transitional Services Agreement

Reverse Transitional Services Agreement

Thomson Reuters Applications, Inc

Minimum

Maximum

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Consideration for fixed assets transferred

'

'

'

'

'

'

'

'

'

'

'

'

$15,975,000

Minimum annual advisory fee payment to Sponsor

'

'

2,500,000

'

'

'

'

'

'

'

'

'

'

Percentage of consolidated EBITDA for advisory fee calculation (in percent)

'

'

2.00%

'

'

'

'

'

'

'

'

'

'

Sponsor advisory fees

1,500,000

2,900,000

'

'

'

'

'

'

'

'

'

'

'

Prepaid Sponsor Advisory Fees

'

700,000

'

'

'

'

'

'

'

'

'

'

'

Acquisition related costs

'

'

'

12,300,000

10,500,000

'

'

'

'

'

'

'

'

Service periods covered in reverse transitional services agreement

'

'

'

'

'

'

'

'1 year

'22 months

'

'

'

'

Income from service agreement reported as a reduction to General and administrative expense

'

'

'

'

'

500,000

700,000

'

'

'

'

'

'

Additional capital contribution

464,400,000

2,350,000

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Contributions from Parent

$0

$2,350,000

'

'

'

'

'

'

'

$2,350,000

$0

$0

'

Fair_Value_Measurement_Details

Fair Value Measurement (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Jun. 06, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Senior Note due 2020

Senior Note due 2020

Senior Note due 2020

Level 1

Level 1

Level 1

Level 1

Level 1

Level 2

Level 2

Level 2

Level 2

Level 2

Level 3

Level 3

Level 3

Level 3

Level 3

Reported Value Measurement

Reported Value Measurement

Reported Value Measurement

Reported Value Measurement

Reported Value Measurement

Senior Notes

Senior Notes

Senior Notes

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Note due 2020

Senior Note due 2020

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Note due 2020

Senior Note due 2020

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Note due 2020

Senior Note due 2020

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Credit Facility Due 2019

Senior Note due 2020

Senior Note due 2020

Term Loan

Term Loan

Line of Credit

Senior Notes

Senior Notes

Term Loan

Term Loan

Line of Credit

Senior Notes

Senior Notes

Term Loan

Term Loan

Line of Credit

Senior Notes

Senior Notes

Term Loan

Term Loan

Line of Credit

Senior Notes

Senior Notes

Secured Debt

Secured Debt

Revolving Credit Facility

Secured Debt

Secured Debt

Revolving Credit Facility

Secured Debt

Secured Debt

Revolving Credit Facility

Secured Debt

Secured Debt

Revolving Credit Facility

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stated interest rate on Senior Notes (in percent)

'

'

'

10.63%

10.63%

10.63%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair values

'

'

'

'

'

'

$0

$0

$0

$0

$0

$531,625

$528,242

$30,000

$369,876

$348,415

$0

$0

$0

$0

$0

$516,831

$512,813

$30,000

$325,427

$325,159

Goodwill impairment

$366,662

$0

$366,662

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Subsequent_Events_Details

Subsequent Events (Details) (Line of Credit, Revolving Credit Facility, Senior Credit Facility Due 2019, Subsequent Event, USD $)	0 Months Ended
In Millions, unless otherwise specified	Feb. 14, 2014
Line of Credit | Revolving Credit Facility | Senior Credit Facility Due 2019 | Subsequent Event	'
Subsequent Event [Line Items]	'
Repayments of Debt	$15

Supplemental_Guarantor_Financi1

Supplemental Guarantor Financial Information (Details) (USD $)	Dec. 31, 2013	Jun. 06, 2012
In Thousands, unless otherwise specified	Subsidiary-guarantor	Thomson Reuters (Healthcare) Inc. (TRHI)
Condensed Financial Statements, Captions [Line Items]	'	'
Ownership percentage wholly owned subsidiary	100.00%	'
Number of subsidiary guarantors	0	'
Acquisition related costs	'	$26,734

Supplemental_condensed_financi2

Supplemental condensed financial information of the Parent Company Parent Company Condensed Balance Sheet (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Condensed Balance Sheet Statements, Captions [Line Items]	'	'
Total assets	$1,164,603	$1,597,127
Total liabilities	1,085,320	1,177,875
Common stock—$0.01 par value; 1,000 shares authorized, 1 share issued and outstanding at December 31, 2013 and 2012	0	0
Additional paid-in capital	478,549	473,364
Accumulated deficit	-399,101	-54,112
Foreign currency translation adjustment	-165	0
Total liabilities and equity	1,164,603	1,597,127
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	1,000	1,000
Common stock, share issued (in shares)	1	1
Common stock, shares outstanding (in shares)	1	1
Truven Holding Corp.	'	'
Condensed Balance Sheet Statements, Captions [Line Items]	'	'
Investments in Truven Health Analytics Inc.	79,283	419,252
Total assets	79,283	419,252
Total liabilities	0	0
Common stock—$0.01 par value; 1,000 shares authorized, 1 share issued and outstanding at December 31, 2013 and 2012	0	0
Additional paid-in capital	478,549	473,364
Accumulated deficit	-399,101	-54,112
Foreign currency translation adjustment	-165	0
Total liabilities and equity	$79,283	$419,252
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	1,000	1,000
Common stock, share issued (in shares)	1	1
Common stock, shares outstanding (in shares)	1	1

Supplemental_condensed_financi3

Supplemental condensed financial information of the Parent Company Parent Company Condensed Statement of Comprehensive Loss (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2013
Condensed Income Statements, Captions [Line Items]	'	'
Revenues, net	$241,786	$492,702
Operating costs and expenses	276,877	852,013
Income (loss) before income taxes	-84,105	-429,916
Benefit from (provision for) income taxes	-29,993	-84,927
Net income (loss)	-54,112	-344,989
Foreign currency translation adjustments	0	-165
Total comprehensive income (loss)	-54,112	-345,154
Truven Holding Corp.	'	'
Condensed Income Statements, Captions [Line Items]	'	'
Revenues, net	0	0
Operating costs and expenses	0	0
Income (loss) before income taxes	0	0
Benefit from (provision for) income taxes	0	0
Income before share in net loss from subsidiaries	0	0
Share of net loss from subsidiaries	-54,112	-344,989
Net income (loss)	-54,112	-344,989
Foreign currency translation adjustments	0	-165
Total comprehensive income (loss)	($54,112)	($345,154)

Supplemental_condensed_financi4

Supplemental condensed financial information of the Parent Company Parent Company Condensed Statement of Cash Flows (Details) (USD $)	9 Months Ended	12 Months Ended			9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2013	Sep. 30, 2012	Apr. 19, 2012	Dec. 31, 2012	Dec. 31, 2013	Apr. 19, 2012
					Truven Holding Corp.	Truven Holding Corp.	Truven Holding Corp.
Condensed Cash Flow Statements, Captions [Line Items]	'	'	'	'	'	'	'
Net cash provided by operating activities	$27,352	($1,365)	'	'	$0	$0	'
Investment in Truven Health Analytics, Inc.	'	'	'	'	-464,400	-2,350	'
Net cash used in investing activities	-1,280,672	-43,785	'	'	-464,400	-2,350	'
Issuance of common stock	464,400	0	'	'	464,400	0	'
Additional capital contribution	0	2,350	'	'	0	2,350	'
Net cash provided by (used in) financing activities	1,277,125	31,765	'	'	464,400	2,350	'
Increase (decrease) in cash and cash equivalents	23,805	-13,550	'	'	0	0	'
Beginning of period	'	23,805	23,805	0	'	0	0
End of period	$23,805	$10,255	$23,805	$0	$0	$0	$0

Supplemental_condensed_financi5

Supplemental condensed financial information of the Parent Company Narrative (Details) (USD $)	0 Months Ended	9 Months Ended	12 Months Ended	5 Months Ended	12 Months Ended	0 Months Ended	9 Months Ended	12 Months Ended	2 Months Ended	0 Months Ended
	Jun. 06, 2012	Dec. 31, 2012	Dec. 31, 2013	Jun. 06, 2012	Dec. 31, 2011	Apr. 20, 2012	Dec. 31, 2012	Dec. 31, 2013	Jun. 06, 2012	Mar. 31, 2012	Mar. 31, 2012
				Predecessor	Predecessor	Truven Holding Corp.	Truven Holding Corp.	Truven Holding Corp.	Thomson Reuters (Healthcare) Inc. (TRHI)	Minimum	Maximum
									Predecessor	Thomson Reuters (Healthcare) Inc. (TRHI)	Thomson Reuters (Healthcare) Inc. (TRHI)
Condensed Financial Statements, Captions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Restricted net assets	'	$1,597,127,000	$1,164,603,000	'	'	'	$419,252,000	$79,283,000	'	'	'
Percentage of Consolidated Net Assets	'	'	'	'	'	'	25.00%	25.00%	'	'	'
Common stock, shares authorized (in shares)	'	1,000	1,000	'	'	'	1,000	1,000	'	'	'
Common stock, share issued (in shares)	'	1	1	'	'	'	1	1	'	'	'
Common stock, par value (in dollars per share)	'	$0.01	$0.01	'	'	'	$0.01	$0.01	'	'	'
Issuance of common stock	464,400,000	464,400,000	0	0	0	464,400,000	464,400,000	0	'	'	'
Business Combination, Contingent Consideraton Arrangements, Retention and Bonus Payment Eligibility, Requisite Service Period	'	'	'	'	'	'	'	'	'	'90 days	'1 year
Retention Bonus Related to Acquisition	'	'	'	'	'	'	15,813,000,000	'	'	'	'
Payments of Retention Bonus Related to Acquisition	'	'	'	'	'	'	8,635,000,000	1,378,000,000	5,800,000,000	'	'
Proceeds from Contributions from Parent	'	$0	$2,350,000	$0	$0	'	$0	$2,350,000	'	'	'

Valuation_and_Qualifying_Accou1

Valuation and Qualifying Accounts (Details) (Allowance for Doubtful Accounts, USD $)	9 Months Ended		12 Months Ended		5 Months Ended		12 Months Ended
	Dec. 31, 2012		Dec. 31, 2013		Jun. 06, 2012		Dec. 31, 2011
	Successor		Successor		Predecessor		Predecessor
Movement in Valuation Allowances and Reserves [Roll Forward]	'		'		'		'
Balance at Beginning of Year	$0		$1,865,000		$1,319,000		$850,000
Charge to (Recovery from) Bad Debt	517,000	[1]	-144,000	[1]	0	[1]	466,000	[1]
Writeoffs Net of Recoveries	-1,348,000	[2]	191,000	[2]	1,319,000	[2]	-3,000	[2]
Balance at End of Year	$1,865,000		$1,530,000		$0		$1,319,000
[1]	Additions to the allowance account through the normal course of business are charged to expense.
[2]	Write-offs reduce the balance of accounts receivable and the related allowance for doubtful accounts indicating management’s belief that specific balances are not recoverable.